1
|
Musto C, Cerri J, Capizzi D, Fontana MC, Rubini S, Merialdi G, Berzi D, Ciuti F, Santi A, Rossi A, Barsi F, Gelmini L, Fiorentini L, Pupillo G, Torreggiani C, Bianchi A, Gazzola A, Prati P, Sala G, Apollonio M, Delogu M, Biancardi A, Uboldi L, Moretti A, Garbarino C. First evidence of widespread positivity to anticoagulant rodenticides in grey wolves (Canis lupus). Sci Total Environ 2024; 915:169990. [PMID: 38232835 DOI: 10.1016/j.scitotenv.2024.169990] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/06/2023] [Revised: 01/05/2024] [Accepted: 01/05/2024] [Indexed: 01/19/2024]
Abstract
Second-generation Anticoagulant Rodenticides (ARs) can be critical for carnivores, due to their widespread use and impacts. However, although many studies explored the impacts of ARs on small and mesocarnivores, none assessed the extent to which they could contaminate large carnivores in anthropized landscapes. We filled this gap by exploring spatiotemporal trends in grey wolf (Canis lupus) exposure to ARs in central and northern Italy, by subjecting a large sample of dead wolves (n = 186) to the LC-MS/MS method. Most wolves (n = 115/186, 61.8 %) tested positive for ARs (1 compound, n = 36; 2 compounds, n = 47; 3 compounds, n = 16; 4 or more compounds, n = 16). Bromadiolone, brodifacoum and difenacoum, were the most common compounds, with brodifacoum and bromadiolone being the ARs that co-occurred the most (n = 61). Both the probability of testing positive for multiple ARs and the concentration of brodifacoum, and bromadiolone in the liver, systematically increased in wolves that were found at more anthropized sites. Moreover, wolves became more likely to test positive for ARs through time, particularly after 2020. Our results underline that rodent control, based on ARs, increases the risks of unintentional poisoning of non-target wildlife. However, this risk does not only involve small and mesocarnivores, but also large carnivores at the top of the food chain, such as wolves. Therefore, rodent control is adding one further conservation threat to endangered large carnivores in anthropized landscapes of Europe, whose severity could increase over time and be far higher than previously thought. Large-scale monitoring schemes for ARs in European large carnivores should be devised as soon as possible.
Collapse
Affiliation(s)
- Carmela Musto
- Department of Veterinary Medical Sciences, University of Bologna, 40064 Bologna, Italy.
| | - Jacopo Cerri
- Department of Veterinary Medicine, University of Sassari, 07100 Sassari, Italy.
| | - Dario Capizzi
- Directorate for Environment, Latium Region, 00173 Rome, Italy
| | - Maria Cristina Fontana
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Silva Rubini
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Giuseppe Merialdi
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Duccio Berzi
- Centro per lo Studio e la Documentazione sul Lupo, 50033 Firenze, Italy
| | - Francesca Ciuti
- Centro per lo Studio e la Documentazione sul Lupo, 50033 Firenze, Italy
| | - Annalisa Santi
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Arianna Rossi
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Filippo Barsi
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Luca Gelmini
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Laura Fiorentini
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Giovanni Pupillo
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Camilla Torreggiani
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Alessandro Bianchi
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Alessandra Gazzola
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Paola Prati
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Giovanni Sala
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Marco Apollonio
- Department of Veterinary Medicine, University of Sassari, 07100 Sassari, Italy
| | - Mauro Delogu
- Department of Veterinary Medical Sciences, University of Bologna, 40064 Bologna, Italy
| | - Alberto Biancardi
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Laura Uboldi
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Alessandro Moretti
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| | - Chiara Garbarino
- Istituto Zooprofilattico della Lombardia e dell'Emilia-Romagna "B. Ubertini", 25124 Brescia, Italy
| |
Collapse
|
2
|
Penserini L, Moretti A, Mainardis M, Cantoni B, Antonelli M. Tackling climate change through wastewater reuse in agriculture: A prioritization methodology. Sci Total Environ 2024; 914:169862. [PMID: 38185141 DOI: 10.1016/j.scitotenv.2023.169862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/13/2023] [Revised: 12/20/2023] [Accepted: 12/31/2023] [Indexed: 01/09/2024]
Abstract
Water shortages, exacerbated by climate change, are posing a major global challenge, particularly impacting the agricultural sector. A growing interest is raised towards reclaimed wastewater (RWW) as an alternative irrigation source, capable of exploiting also the nutrient content through the fertigation practice. However, a prioritization methodology for selecting the most appropriate wastewater treatment plants (WWTPs) for implementing direct RWW reuse is currently missing. Such prioritization would benefit water utilities, often managing several WWTPs, and policymakers in optimizing economic asset allocation. In this work, a prioritization framework is proposed to evaluate WWTPs' suitability for implementing direct RWW reuse considering both WWTP and surrounding territory characteristics. This procedure consists of four key steps. Firstly, a techno-economic model was developed, in which monthly mass balances on water and nutrients are solved by matching crop requirements, rainfall conditions, and effluent characteristics. Economic suitability was quantified considering economic benefits due to savings in freshwater resource, mineral fertilizers and avoided greenhouse gases emissions, but also losses in crop yield due to RWW salinity content. Secondly, a classification procedure was coded to select representative WWTPs among a set of WWTPs, based on their size, presence of nutrient removal processes, and type of crops in their surroundings. The techno-economic model was then applied to these selected WWTPs. Thirdly, input parameters' relevance in determining WWTP suitability for RWW reuse was ranked. Finally, scenario analyses were conducted to study the influence of rainfall patterns and nutrient treatment removal on the RWW reuse feasibility. The type of crops surrounding the WWTPs and RWW salinity content resulted to be crucial elements in determining WWTPs suitability for RWW reuse implementation. The proposed methodology proved to be an effective support tool for policymakers and water utilities to assess the techno-economic feasibility of direct RWW reuse, generalizing results to several combinations of WWTPs and crops.
Collapse
Affiliation(s)
- Luca Penserini
- Politecnico Milano, Department of Civil and Environmental Engineering (DICA) - Environmental Section, Piazza Leonardo da Vinci 32, 20133 Milano, Italy
| | - Alessandro Moretti
- Università degli studi di Udine, Polytechnic Department of Engineering and Architecture (DPIA), Via del Cotonificio 108, 33100 Udine, Italy
| | - Matia Mainardis
- Università degli studi di Udine, Polytechnic Department of Engineering and Architecture (DPIA), Via del Cotonificio 108, 33100 Udine, Italy
| | - Beatrice Cantoni
- Politecnico Milano, Department of Civil and Environmental Engineering (DICA) - Environmental Section, Piazza Leonardo da Vinci 32, 20133 Milano, Italy
| | - Manuela Antonelli
- Politecnico Milano, Department of Civil and Environmental Engineering (DICA) - Environmental Section, Piazza Leonardo da Vinci 32, 20133 Milano, Italy.
| |
Collapse
|
3
|
Vitale E, Bizzoca D, Di Dio F, Moretti A, Moretti B. The gender role in the publishing of Authorships in high-impact orthopedic journals. Musculoskelet Surg 2024:10.1007/s12306-023-00810-0. [PMID: 38265562 DOI: 10.1007/s12306-023-00810-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2022] [Accepted: 12/27/2023] [Indexed: 01/25/2024]
Abstract
To evidence the existence of a gender gap in the orthopedic scientific literature by including also differences between some specific orthopedic surgery specialities, such as hands and feet. Then, we also considered gender role in the Authorship linked with the economic wealth of each country belonging to each Author. The gender of the first Authors of journals on orthopedics and sports medicine indexing in the Scopus database with the highest impact factor (IF) related to the year 2019, for the period from January 1, 2015, to December 31, 2020, were considered. A total of 11 journals were considered, including a total of 5474 articles, 1087 (19.86%) had a woman as the first Author and 4387 (80.14%) a man. During the studied period, the trend seems to be the same (p = 0.906): Men were significantly more producing than women in the orthopedic field both by considering the topic of the journal (p = .003), all the most impacted orthopedic journals (p < 0.001) and economies (p < 0.001). There was therefore a strong significance: In the orthopedic field, there were significantly more male researchers who presented their first name in scientific publications compared to females in all orthopedic subspecialties. The economically poorer countries published less and the role of women became almost absent.
Collapse
Affiliation(s)
- E Vitale
- Mental Health Center Modugno (Bari), Local Health Authority Bari, Bari, Italy.
| | - D Bizzoca
- Orthopaedic and Trauma Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs, School of Medicine, University of Bari "Aldo Moro", AOU Consorziale "Policlinico", Bari, Italy
| | - F Di Dio
- Student Masterr's Degree in Nursing and Midwifery, University of Bari Aldo Moro, Bari, Italy
| | - A Moretti
- Italian Group for Health and Gender, Bari, Italy
| | - B Moretti
- Orthopaedic and Trauma Unit, Department of Basic Medical Sciences, Neuroscience and Sense Organs, School of Medicine, University of Bari "Aldo Moro", AOU Consorziale "Policlinico", Bari, Italy
| |
Collapse
|
4
|
Tonelli R, Castaniere I, Cortegiani A, Tabbì L, Fantini R, Andrisani D, Gozzi F, Moretti A, Bruzzi G, Manicardi L, Cerbone C, Nani C, Biagioni E, Cerri S, Samarelli V, Busani S, Girardis M, Marchioni A, Clini E. Inspiratory Effort and Respiratory Mechanics in Patients with Acute Exacerbation of Idiopathic Pulmonary fibrosis: A Preliminary Matched Control Study. Pulmonology 2023; 29:469-477. [PMID: 36180352 DOI: 10.1016/j.pulmoe.2022.08.004] [Citation(s) in RCA: 3] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/08/2022] [Revised: 08/03/2022] [Accepted: 08/04/2022] [Indexed: 11/25/2022] Open
Abstract
BACKGROUND Patients with acute exacerbation of idiopathic pulmonary fibrosis (AE-IPF) may experience severe acute respiratory failure, even requiring ventilatory assistance. Physiological data on lung mechanics during these events are lacking. METHODS Patients with AE-IPF admitted to Respiratory Intensive Care Unit to receive non-invasive ventilation (NIV) were retrospectively analyzed. Esophageal pressure swing (ΔPes) and respiratory mechanics before and after 2 hours of NIV were collected as primary outcome. The correlation between positive end-expiratory pressure (PEEP) levels and changes of in dynamic compliance (dynCRS) and PaO2/FiO2 ratio was assessed. Further, an exploratory comparison with a historical cohort of ARDS patients matched 1:1 by age, sequential organ failure assessment score, body mass index and PaO2/FiO2 level was performed. RESULTS At baseline, AE-IPF patients presented a high respiratory drive activation with ΔPes = 27 (21-34) cmH2O, respiratory rate (RR) = 34 (30-39) bpm and minute ventilation (VE) = 21 (20-26) L/min. Two hours after NIV application, ΔPes, RR and VE values showed a significant reduction (16 [14-24] cmH2O, p<0.0001, 27 [25-30] bpm, p=0.001, and 18 [17-20] L/min, p=0.003, respectively) while no significant change was found in dynamic transpulmonary pressure, expiratory tidal volume (Vte), dynCRS and dynamic mechanical power. PEEP levels negatively correlated with PaO2/FiO2 ratio and dynCRS (r=-0.67, p=0.03 and r=-0.27, p=0.4, respectively). When compared to AE-IPF, ARDS patients presented lower baseline ΔPes, RR, VE and dynamic mechanical power. Differently from AE-IPF, in ARDS both Vte and dynCRS increased significantly following NIV (p=0.01 and p=0.004 respectively) with PEEP levels directly associated with PaO2/FiO2 ratio and dynCRS (r=0.24, p=0.5 and r=0.65, p=0.04, respectively). CONCLUSIONS In this study, patients with AE-IPF showed a high inspiratory effort, whose intensity was reduced by NIV application without a significant improvement in respiratory mechanics. In an exploratory analysis, AE-IPF patients showed a different mechanical behavior under spontaneous unassisted and assisted breathing compared with ARDS patients of similar severity.
Collapse
Affiliation(s)
- R Tonelli
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - I Castaniere
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - A Cortegiani
- Department of Surgical, Oncological and Oral Science (Di.Chir.On.S.), University of Palermo, Italy; Department of Anesthesia, Intensive Care and Emergency, Policlinico Paolo Giaccone, Palermo, Italy
| | - L Tabbì
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy
| | - R Fantini
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy
| | - D Andrisani
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - F Gozzi
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Clinical and Experimental Medicine PhD Program, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - A Moretti
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - G Bruzzi
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - L Manicardi
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - C Cerbone
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy
| | - C Nani
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy
| | - E Biagioni
- Intensive Care Unit, University Hospital of Modena, Italy
| | - S Cerri
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - V Samarelli
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| | - S Busani
- Intensive Care Unit, University Hospital of Modena, Italy
| | - M Girardis
- Intensive Care Unit, University Hospital of Modena, Italy
| | - A Marchioni
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy.
| | - E Clini
- University Hospital of Modena, Respiratory Diseases Unit, Department of Medical and Surgical Sciences, University of Modena Reggio Emilia, Modena, Italy; Laboratory of Cell Therapies and Respiratory Medicine, Department of Medical and Surgical Sciences for Children & Adults University Hospital of Modena and Reggio Emilia, Italy
| |
Collapse
|
5
|
Bonavolontà V, Cianferotti L, Iolascon G, Moretti A, Brandi ML, Fischetti F, Lenzi A, Baldari C, Migliaccio S. Which physical activity in patients affected by hypoparathyroidism? A review of the literature and practical recommendations. J Endocrinol Invest 2022; 45:1289-1295. [PMID: 35122630 DOI: 10.1007/s40618-022-01756-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/24/2021] [Accepted: 01/28/2022] [Indexed: 02/08/2023]
Abstract
BACKGROUND Hypoparathyroidism (HypoP) is a rare endocrine condition characterized by hypocalcaemia and hyperphosphatemia, as a consequence of absent or improperly low parathyroid hormone (PTH) levels. Patients affected by HypoP have a clinical condition often characterized by paresthesias and muscle spasms, as well as long-term consequences as nephrolithiasis, extraskeletal calcification, and fractures. In the literature, likely due to these symptoms, few data exist regarding the appropriate physical activity (PA) in subjects suffering from HypoP. PURPOSE This review evaluates the literature on exercise-based approaches to the management of individuals affected by HypoP and evaluates: (1) the effects of physical exercise on muscle cramps and other clinical symptoms; (2) the effects of exercise on PTH and calcium level; (3) the most suitable clinical exercise testing; and (4) the most suitable exercise combination. METHODS AND RESULTS A systematic search was conducted using the databases MEDLINE, Google Scholar using "hypoparathyroidism AND Physical Activity", "Training AND hypoparathyroidism", "Exercise AND muscle cramps", "Exercise AND Fatigue" as keywords. In addition, references list from the included articles were searched and cross-checked to identify any further potentially eligible studies. A total of 50 manuscripts were found among which 39 manuscripts were selected. A few clinical studies have been performed in HypoP patients to evaluate PA training protocols. CONCLUSION Although further research is needed to draw solid conclusions regarding best PA protocols in subjects affected by HypoP, a PA protocol has been proposed within the manuscript to encourage patients to attempt exercise to improve their clinical conditions and their quality of life.
Collapse
Affiliation(s)
- V Bonavolontà
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - L Cianferotti
- Bone Metabolic Diseases Unit, Department of Experimental and Clinical Biomedical Sciences, University of Firenze, Firenze, Italy
| | - G Iolascon
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Napoli, Italy
| | - A Moretti
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Napoli, Italy
| | | | - F Fischetti
- Department of Basic Medical Sciences, Neuroscience and Sense Organs, University of Bari "Aldo Moro", Bari, Italy
| | - A Lenzi
- Department of Experimental Medicine, Sapienza University of Roma, Roma, Italy
| | - C Baldari
- Department of Theoretical and Applied Sciences, eCampus University, Roma, Italy
| | - S Migliaccio
- Department of Movement, Human and Health Sciences, University Foro Italico of Roma, Piazza Lauro De Bosis 6, 00195, Roma, Italy.
| |
Collapse
|
6
|
Kagot V, De Boevre M, De Saeger S, Moretti A, Mwamuye M, Okoth S. Incidence of toxigenic Aspergillus and Fusarium species occurring in maize kernels from Kenyan households. WORLD MYCOTOXIN J 2022. [DOI: 10.3920/wmj2021.2748] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
Abstract
Aspergillus and Fusarium are fungal genera that include toxigenic and pathogenic species, able to suffuse farmers’ crops and secrete an array of small molecular weight secondary metabolites which can cause health complications to humans and animals when ingested. In sub-Sahara Africa, contamination and persistence of these fungi is increased by the tropical climatic conditions which are ideal for the fungi to thrive. This study evaluated the incidence, regional distribution and toxigenic potential of Aspergillus and Fusarium species occurring in maize kernels from Eastern, Western, Coastal and the Lake Victoria agro-ecological zones of Kenya. Maize kernels were collected from 16 households in each agro-ecological zone. Single spore technique was used to isolate pure cultures of Aspergillus and Fusarium which were identified morphologically. Further, molecular analysis was done using the internal transcribed spacer 1 (ITS 1) region of the ribosomal DNA for Aspergillus and the translation elongation factor-1 alpha (TEF-1α) for Fusarium. The potential of the isolated fungi to produce mycotoxins was probed by polymerase chain reaction (PCR) based on the aflatoxin regulatory aflaR gene in Aspergillus, and the fumonisin backbone structure gene FUM1 in Fusarium. Among the potentially aflatoxigenic A. flavus species isolated, 55% were from Eastern, 27% from the Coastal zone, 13% from Lake Victoria zone and 5% from Western Kenya. Among the potentially fumonisin producing F. verticillioides isolated, 45% were from the Lake Victoria agro-ecological zone, 30% were from Western, 15% from Eastern Kenya and 10% from the Coastal agro-ecological zone. This study adds data on potential mycotoxin hotspots in Kenya useful in employing targeted and regional mycotoxin mitigation strategies in efforts to avert future mycotoxicoses outbreaks in Kenya.
Collapse
Affiliation(s)
- V. Kagot
- Centre of Excellence in Mycotoxicology & Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
- School of Biological Sciences-University of Nairobi, Riverside Drive, 00100 Nairobi, Kenya
| | - M. De Boevre
- Centre of Excellence in Mycotoxicology & Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
| | - S. De Saeger
- Centre of Excellence in Mycotoxicology & Public Health, Faculty of Pharmaceutical Sciences, Ghent University, Ottergemsesteenweg 460, 9000 Ghent, Belgium
- Department of Biotechnology and Food Technology, Faculty of Science, University of Johannesburg, Doornfontein Campus, P.O. Box 17011, Gauteng, 2028 Johannesburg, South Africa
| | - A. Moretti
- Institute of Sciences of Food Production, CNR, Via Amendola 122/o, 70126 Bari, Italy
| | - M. Mwamuye
- Institute of Parasitology and Tropical Veterinary Medicine, Freie Universität, Robert-von-Ostertag-Str. 7-13, 14163 Berlin, Germany
| | - S. Okoth
- School of Biological Sciences-University of Nairobi, Riverside Drive, 00100 Nairobi, Kenya
| |
Collapse
|
7
|
Chekali S, Ouji A, Somma S, Masiello M, Douihech W, Khemir E, Moretti A, Gargouri S. First Report of Wilt on Lentil ( Lens culinaris) Caused by Fusarium redolens in Tunisia. Plant Dis 2022; 106:1302. [PMID: 34661449 DOI: 10.1094/pdis-08-21-1782-pdn] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/13/2023]
Affiliation(s)
- S Chekali
- Pôle Régional de Recherche-Développement Agricole du Nord-Ouest Semi-Aride au Kef, BP 221, 7100, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
- Laboratoire de Protecion des Végétaux, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
| | - A Ouji
- Pôle Régional de Recherche-Développement Agricole du Nord-Ouest Semi-Aride au Kef, BP 221, 7100, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
- Laboratoire des grandes cultures, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
| | - S Somma
- Research National Council of Italy, Institute of Sciences of Food Production, CNR-ISPA, Bari, Italy
| | - M Masiello
- Research National Council of Italy, Institute of Sciences of Food Production, CNR-ISPA, Bari, Italy
| | - W Douihech
- Pôle Régional de Recherche-Développement Agricole du Nord-Ouest Semi-Aride au Kef, BP 221, 7100, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
| | - E Khemir
- Laboratoire de Protecion des Végétaux, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
| | - A Moretti
- Research National Council of Italy, Institute of Sciences of Food Production, CNR-ISPA, Bari, Italy
| | - S Gargouri
- Laboratoire de Protecion des Végétaux, Institut National de la Recherche Agronomique de Tunisie, 2049, Ariana, Tunisia
| |
Collapse
|
8
|
Mainardis M, Cecconet D, Moretti A, Callegari A, Goi D, Freguia S, Capodaglio AG. Wastewater fertigation in agriculture: Issues and opportunities for improved water management and circular economy. Environ Pollut 2022; 296:118755. [PMID: 34971741 DOI: 10.1016/j.envpol.2021.118755] [Citation(s) in RCA: 24] [Impact Index Per Article: 12.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/20/2021] [Revised: 12/14/2021] [Accepted: 12/25/2021] [Indexed: 06/14/2023]
Abstract
Water shortages are an issue of growing worldwide concern. Irrigated agriculture accounts for about 70% of total freshwater withdrawals globally, therefore alternatives to use of conventional sources need to be investigated. This paper critically reviews the application of treated wastewater for agricultural fertigation (i.e., water and nutrient recovery) considering different perspectives: legislation, agronomic characteristics, social acceptability, sustainability of treatment technologies. Critical issues that still need further investigation for a wider application of fertigation practices include accumulation of emerging contaminants in soils, microbiological and public health implications, and stakeholders' acceptance. A techno-economic methodological approach for assessing the sustainability of treated wastewater reuse in agriculture is subsequently proposed herein, which considers different possible local conditions (cultivated crops and effluent characteristics). The results showed that tailoring effluent characteristics to the desired nutrient composition could enhance the process economic sustainability; however, water savings have a major economic impact than fertilizers' savings, partly due to limited P reuse efficiency. The developed methodology is based on a practical approach and may be generalized to most agricultural conditions, to evaluate and encourage safe and efficient agricultural wastewater reuse practices.
Collapse
Affiliation(s)
- Matia Mainardis
- Department Polytechnic of Engineering and Architecture (DPIA), University of Udine, Via Del Cotonificio 108, 33100, Udine, Italy.
| | - Daniele Cecconet
- Department of Civil Engineering and Architecture, University of Pavia, Via Adolfo Ferrata 3, 27100, Pavia, Italy
| | - Alessandro Moretti
- Department Polytechnic of Engineering and Architecture (DPIA), University of Udine, Via Del Cotonificio 108, 33100, Udine, Italy
| | - Arianna Callegari
- Department of Civil Engineering and Architecture, University of Pavia, Via Adolfo Ferrata 3, 27100, Pavia, Italy
| | - Daniele Goi
- Department Polytechnic of Engineering and Architecture (DPIA), University of Udine, Via Del Cotonificio 108, 33100, Udine, Italy
| | - Stefano Freguia
- Department of Chemical Engineering, Faculty of Engineering & Information Technology, The University of Melbourne, Victoria, 3010, Australia
| | - Andrea G Capodaglio
- Department of Civil Engineering and Architecture, University of Pavia, Via Adolfo Ferrata 3, 27100, Pavia, Italy
| |
Collapse
|
9
|
Mainardis M, Buttazzoni M, Cottes M, Moretti A, Goi D. Respirometry tests in wastewater treatment: Why and how? A critical review. Sci Total Environ 2021; 793:148607. [PMID: 34182438 DOI: 10.1016/j.scitotenv.2021.148607] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/24/2021] [Revised: 06/08/2021] [Accepted: 06/18/2021] [Indexed: 06/13/2023]
Abstract
Respirometry tests are a widely employed method in wastewater treatment field to characterize wastewater streams, assess toxic/inhibitory effects to the biomass, calibrate mathematical models. Respirometry can allow to fractionize the chemical oxygen demand (COD) in biodegradable and inert fractions, but also provide information related to biomass kinetics and stoichiometry through standardized laboratory techniques. Considering the increasing number of emerging contaminants detected in wastewater effluents, such as pharmaceuticals, personal care products and pesticides, respirometry can be a useful tool to promptly assess any toxic or inhibitory effect in wastewater treatment plants (WWTPs) operations. Beside conventional activated sludge (CAS), in recent years respirometric methods have been applied to innovative fields, such as moving-bed bio-reactors (MBBRs), fungi and microalgae, exploiting natural remediation methods. In particular, respirometry application to microalgae, through the so-called photo-respirometry, has been investigated in the latest years in the treatment of high-nutrient loaded streams, allowing resource recovery in biomass form. In this work, respirometric methods are first introduced from a theoretical basis and then critically discussed by considering the experimental apparatus, the available characterization protocols and the fields of application; the most recent literature findings on respirometry are coupled with authors' experience in the field. A comparison between physicochemical methods and respirometry is made, considering common protocols for WWTP modelling and calibration. The future research needed on the topic is finally outlined, including the coupling of respirometry with microbial community analysis, potentially leading to an enhanced process understanding, an extended respirometry utilization to get specific kinetic and stoichiometric parameters for modelling purposes, and a wider respirometry application as diagnosis tool in WWTP operations.
Collapse
Affiliation(s)
- Matia Mainardis
- Department Polytechnic of Engineering and Architecture, University of Udine, Via del Cotonificio 108, 33100 Udine, Italy.
| | - Marco Buttazzoni
- Department Polytechnic of Engineering and Architecture, University of Udine, Via del Cotonificio 108, 33100 Udine, Italy
| | - Mattia Cottes
- Department Polytechnic of Engineering and Architecture, University of Udine, Via del Cotonificio 108, 33100 Udine, Italy
| | - Alessandro Moretti
- Department Polytechnic of Engineering and Architecture, University of Udine, Via del Cotonificio 108, 33100 Udine, Italy
| | - Daniele Goi
- Department Polytechnic of Engineering and Architecture, University of Udine, Via del Cotonificio 108, 33100 Udine, Italy
| |
Collapse
|
10
|
Maraia Z, Ricci D, Rocchi MBL, Moretti A, Bufarini C, Cavaliere A, Peverini M. Real-Life Analysis with Erenumab: First Target Therapy in the Episodic and Chronic Migraine's Prophylaxis. J Clin Med 2021; 10:jcm10194425. [PMID: 34640442 PMCID: PMC8509525 DOI: 10.3390/jcm10194425] [Citation(s) in RCA: 7] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Revised: 09/20/2021] [Accepted: 09/24/2021] [Indexed: 11/16/2022] Open
Abstract
Background: to research retrospectively the efficacy of Erenumab’s treatment, thus allowing to describe a summary more in line with the reality observed every day in clinical practice, relative to a sample of patients widely heterogeneous. The study aims to confirm the efficacy of Erenumab, in terms of reduction of migraine days per month, from baseline to month 12 of treatment. Additional objectives included a reduction in the number of days of symptomatic drug use and change from baseline in the Migraine Disability Assessment Score Questionnaire (MIDAS); Methods: the analysis included all patients treated for 12 months with Erenumab during the year 2019–2020. The population analyzed consists of twenty-six patients from the Neurology outpatient clinic in Fossombrone. Several quantitative and qualitative variables were recorded by reading the medical records of the patients. The MIDAS was administered to patients to assess the disability related to migraine; Results: at the end of treatment, a statistically significant reduction in the mean number of monthly migraine days, acute medication use per month, and MIDAS questionnaire score was observed; Conclusions: as a preventive treatment of episodic and chronic migraine, our analysis data confirm the efficacy of Erenumab for the prevention of the migraine. The success is achieved in 96% of cases.
Collapse
Affiliation(s)
- Zaira Maraia
- Biomolecular Sciences Department, University of Urbino, 61029 Urbino, Italy; (Z.M.); (D.R.); (M.B.L.R.)
| | - Diletta Ricci
- Biomolecular Sciences Department, University of Urbino, 61029 Urbino, Italy; (Z.M.); (D.R.); (M.B.L.R.)
| | - Marco Bruno Luigi Rocchi
- Biomolecular Sciences Department, University of Urbino, 61029 Urbino, Italy; (Z.M.); (D.R.); (M.B.L.R.)
| | - Alessandro Moretti
- Neurological Centre for Cognitive Disorders and Dementia, ASUR Marche AV1, 61034 Fossombrone, Italy;
| | | | - Arturo Cavaliere
- Local Pharmaceutical Service, Viterbo Local Health Authority, 01100 Viterbo, Italy;
| | - Manola Peverini
- Urbino Hospital Pharmacy, ASUR Marche AV1, 61029 Urbino, Italy;
- Correspondence: ; Tel.: +39-328-8427343
| |
Collapse
|
11
|
Moretti A. The im pact of climate change on mycotoxin and related fungi risks in Europe: current scenario and future perspectives. Toxicol Lett 2021. [DOI: 10.1016/s0378-4274(21)00321-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022]
|
12
|
Alexeev GD, Alexeev MG, Amoroso A, Andrieux V, Anosov V, Antoshkin A, Augsten K, Augustyniak W, Azevedo CDR, Badełek B, Balestra F, Ball M, Barth J, Beck R, Bedfer Y, Berenguer Antequera J, Bernhard J, Bodlak M, Bradamante F, Bressan A, Burtsev VE, Chang WC, Chatterjee C, Chiosso M, Chumakov AG, Chung SU, Cicuttin A, Correia PMM, Crespo ML, D'Ago D, Dalla Torre S, Dasgupta SS, Dasgupta S, Denisenko I, Denisov OY, Donskov SV, Doshita N, Dreisbach C, Dünnweber W, Dusaev RR, Efremov A, Eversheim PD, Faccioli P, Faessler M, Finger M, Finger M, Fischer H, Franco C, Friedrich JM, Frolov V, Gautheron F, Gavrichtchouk OP, Gerassimov S, Giarra J, Gnesi I, Gorzellik M, Grasso A, Gridin A, Grosse Perdekamp M, Grube B, Guskov A, von Harrach D, Heitz R, Herrmann F, Horikawa N, d'Hose N, Hsieh CY, Huber S, Ishimoto S, Ivanov A, Iwata T, Jandek M, Jary V, Joosten R, Jörg P, Kabuß E, Kaspar F, Kerbizi A, Ketzer B, Khaustov GV, Khokhlov YA, Kisselev Y, Klein F, Koivuniemi JH, Kolosov VN, Kondo Horikawa K, Konorov I, Konstantinov VF, Kotzinian AM, Kouznetsov OM, Koval A, Kral Z, Krinner F, Kulinich Y, Kunne F, Kurek K, Kurjata RP, Kveton A, Lavickova K, Levorato S, Lian YS, Lichtenstadt J, Lin PJ, Longo R, Lyubovitskij VE, Maggiora A, Magnon A, Makins N, Makke N, Mallot GK, Maltsev A, Mamon SA, Marianski B, Martin A, Marzec J, Matoušek J, Matsuda T, Mattson G, Meshcheryakov GV, Meyer M, Meyer W, Mikhailov YV, Mikhasenko M, Mitrofanov E, Mitrofanov N, Miyachi Y, Moretti A, Nagaytsev A, Naim C, Neyret D, Nový J, Nowak WD, Nukazuka G, Nunes AS, Olshevsky AG, Ostrick M, Panzieri D, Parsamyan B, Paul S, Pekeler H, Peng JC, Pešek M, Peshekhonov DV, Pešková M, Pierre N, Platchkov S, Pochodzalla J, Polyakov VA, Pretz J, Quaresma M, Quintans C, Reicherz G, Riedl C, Rudnicki T, Ryabchikov DI, Rybnikov A, Rychter A, Samoylenko VD, Sandacz A, Sarkar S, Savin IA, Sbrizzai G, Schmieden H, Selyunin A, Sinha L, Slunecka M, Smolik J, Srnka A, Steffen D, Stolarski M, Subrt O, Sulc M, Suzuki H, Sznajder P, Tessaro S, Tessarotto F, Thiel A, Tomsa J, Tosello F, Townsend A, Tskhay V, Uhl S, Vasilishin BI, Vauth A, Veit BM, Veloso J, Ventura B, Vidon A, Virius M, Wagner M, Wallner S, Zaremba K, Zavada P, Zavertyaev M, Zemko M, Zemlyanichkina E, Zhao Y, Ziembicki M. Triangle Singularity as the Origin of the a_{1}(1420). Phys Rev Lett 2021; 127:082501. [PMID: 34477443 DOI: 10.1103/physrevlett.127.082501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/03/2020] [Revised: 05/04/2021] [Accepted: 05/26/2021] [Indexed: 06/13/2023]
Abstract
The COMPASS Collaboration experiment recently discovered a new isovector resonancelike signal with axial-vector quantum numbers, the a_{1}(1420), decaying to f_{0}(980)π. With a mass too close to and a width smaller than the axial-vector ground state a_{1}(1260), it was immediately interpreted as a new light exotic meson, similar to the X, Y, Z states in the hidden-charm sector. We show that a resonancelike signal fully matching the experimental data is produced by the decay of the a_{1}(1260) resonance into K^{*}(→Kπ)K[over ¯] and subsequent rescattering through a triangle singularity into the coupled f_{0}(980)π channel. The amplitude for this process is calculated using a new approach based on dispersion relations. The triangle-singularity model is fitted to the partial-wave data of the COMPASS experiment. Despite having fewer parameters, this fit shows a slightly better quality than the one using a resonance hypothesis and thus eliminates the need for an additional resonance in order to describe the data. We thereby demonstrate for the first time in the light-meson sector that a resonancelike structure in the experimental data can be described by rescattering through a triangle singularity, providing evidence for a genuine three-body effect.
Collapse
Affiliation(s)
- G D Alexeev
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M G Alexeev
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - A Amoroso
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - V Andrieux
- CERN, 1211 Geneva 23, Switzerland
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - V Anosov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - A Antoshkin
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - K Augsten
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - W Augustyniak
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - C D R Azevedo
- Department of Physics, University of Aveiro, I3N, 3810-193 Aveiro, Portugal
| | - B Badełek
- Faculty of Physics, University of Warsaw, 02-093 Warsaw, Poland
| | - F Balestra
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - M Ball
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - J Barth
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - R Beck
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - Y Bedfer
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - J Berenguer Antequera
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - J Bernhard
- CERN, 1211 Geneva 23, Switzerland
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - M Bodlak
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | | | - A Bressan
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - V E Burtsev
- Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - W-C Chang
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
| | - C Chatterjee
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - M Chiosso
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - A G Chumakov
- Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - S-U Chung
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - A Cicuttin
- Trieste Section of INFN, 34127 Trieste, Italy
| | - P M M Correia
- Department of Physics, University of Aveiro, I3N, 3810-193 Aveiro, Portugal
| | - M L Crespo
- Trieste Section of INFN, 34127 Trieste, Italy
| | - D D'Ago
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | | | - S S Dasgupta
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
| | - S Dasgupta
- Trieste Section of INFN, 34127 Trieste, Italy
| | - I Denisenko
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | | | - S V Donskov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - N Doshita
- Yamagata University, Yamagata 992-8510, Japan
| | - Ch Dreisbach
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - W Dünnweber
- Department of Physics, University of Aveiro, I3N, 3810-193 Aveiro, Portugal
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
- Institute of Scientific Instruments of the CAS, 61264 Brno, Czech Republic
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- CERN, 1211 Geneva 23, Switzerland
- Technical University in Liberec, 46117 Liberec, Czech Republic
- LIP, 1649-003 Lisbon, Portugal
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
- University of Miyazaki, Miyazaki 889-2192, Japan
- Lebedev Physical Institute, 119991 Moscow, Russia
- Physik Department, Technische Universität München, 85748 Garching, Germany
- Nagoya University, 464 Nagoya, Japan
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
- Czech Technical University in Prague, 16636 Prague, Czech Republic
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
- School of Physics and Astronomy, Tel Aviv University, 69978 Tel Aviv, Israel
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
- Tomsk Polytechnic University, 634050 Tomsk, Russia
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
- Faculty of Physics, University of Warsaw, 02-093 Warsaw, Poland
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
- Yamagata University, Yamagata 992-8510, Japan
| | - R R Dusaev
- Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - A Efremov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - P D Eversheim
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | | | - M Faessler
- Department of Physics, University of Aveiro, I3N, 3810-193 Aveiro, Portugal
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
- Institute of Scientific Instruments of the CAS, 61264 Brno, Czech Republic
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- CERN, 1211 Geneva 23, Switzerland
- Technical University in Liberec, 46117 Liberec, Czech Republic
- LIP, 1649-003 Lisbon, Portugal
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
- University of Miyazaki, Miyazaki 889-2192, Japan
- Lebedev Physical Institute, 119991 Moscow, Russia
- Physik Department, Technische Universität München, 85748 Garching, Germany
- Nagoya University, 464 Nagoya, Japan
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
- Czech Technical University in Prague, 16636 Prague, Czech Republic
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
- School of Physics and Astronomy, Tel Aviv University, 69978 Tel Aviv, Israel
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
- Tomsk Polytechnic University, 634050 Tomsk, Russia
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
- Faculty of Physics, University of Warsaw, 02-093 Warsaw, Poland
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
- Yamagata University, Yamagata 992-8510, Japan
| | - M Finger
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - M Finger
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - H Fischer
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | | | - J M Friedrich
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - V Frolov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
- CERN, 1211 Geneva 23, Switzerland
| | - F Gautheron
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - O P Gavrichtchouk
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - S Gerassimov
- Lebedev Physical Institute, 119991 Moscow, Russia
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - J Giarra
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - I Gnesi
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - M Gorzellik
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - A Grasso
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - A Gridin
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Grosse Perdekamp
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - B Grube
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - A Guskov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - D von Harrach
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - R Heitz
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - F Herrmann
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | | | - N d'Hose
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - C-Y Hsieh
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
| | - S Huber
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - S Ishimoto
- Yamagata University, Yamagata 992-8510, Japan
| | - A Ivanov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - T Iwata
- Yamagata University, Yamagata 992-8510, Japan
| | - M Jandek
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - V Jary
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - R Joosten
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - P Jörg
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
| | - E Kabuß
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - F Kaspar
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - A Kerbizi
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - B Ketzer
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - G V Khaustov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - Yu A Khokhlov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - Yu Kisselev
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - F Klein
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
| | - J H Koivuniemi
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - V N Kolosov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | | | - I Konorov
- Lebedev Physical Institute, 119991 Moscow, Russia
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - V F Konstantinov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | | | - O M Kouznetsov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - A Koval
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - Z Kral
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - F Krinner
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - Y Kulinich
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - F Kunne
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - K Kurek
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - R P Kurjata
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
| | - A Kveton
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - K Lavickova
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - S Levorato
- CERN, 1211 Geneva 23, Switzerland
- Trieste Section of INFN, 34127 Trieste, Italy
| | - Y-S Lian
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
| | - J Lichtenstadt
- School of Physics and Astronomy, Tel Aviv University, 69978 Tel Aviv, Israel
| | - P-J Lin
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - R Longo
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | | | - A Maggiora
- Torino Section of INFN, 10125 Torino, Italy
| | - A Magnon
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
| | - N Makins
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - N Makke
- Trieste Section of INFN, 34127 Trieste, Italy
| | - G K Mallot
- Physikalisches Institut, Universität Freiburg, 79104 Freiburg, Germany
- CERN, 1211 Geneva 23, Switzerland
| | - A Maltsev
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - S A Mamon
- Tomsk Polytechnic University, 634050 Tomsk, Russia
| | - B Marianski
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - A Martin
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - J Marzec
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
| | - J Matoušek
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - T Matsuda
- University of Miyazaki, Miyazaki 889-2192, Japan
| | - G Mattson
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - G V Meshcheryakov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Meyer
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - W Meyer
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
| | - Yu V Mikhailov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - M Mikhasenko
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
- CERN, 1211 Geneva 23, Switzerland
| | - E Mitrofanov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - N Mitrofanov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - Y Miyachi
- Yamagata University, Yamagata 992-8510, Japan
| | - A Moretti
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - A Nagaytsev
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - C Naim
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - D Neyret
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - J Nový
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - W-D Nowak
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - G Nukazuka
- Yamagata University, Yamagata 992-8510, Japan
| | | | - A G Olshevsky
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Ostrick
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - D Panzieri
- Torino Section of INFN, 10125 Torino, Italy
| | - B Parsamyan
- Department of Physics, University of Torino, 10125 Torino, Italy
- Torino Section of INFN, 10125 Torino, Italy
| | - S Paul
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - H Pekeler
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - J-C Peng
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - M Pešek
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - D V Peshekhonov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Pešková
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - N Pierre
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - S Platchkov
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - J Pochodzalla
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - V A Polyakov
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - J Pretz
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
| | - M Quaresma
- LIP, 1649-003 Lisbon, Portugal
- Academia Sinica, Institute of Physics, Taipei 11529, Taiwan
| | | | - G Reicherz
- Institut für Experimentalphysik, Universität Bochum, 44780 Bochum, Germany
| | - C Riedl
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - T Rudnicki
- Faculty of Physics, University of Warsaw, 02-093 Warsaw, Poland
| | - D I Ryabchikov
- Physik Department, Technische Universität München, 85748 Garching, Germany
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - A Rybnikov
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - A Rychter
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
| | - V D Samoylenko
- State Scientific Center Institute for High Energy Physics of National Research Center "Kurchatov Institute," 142281 Protvino, Russia
| | - A Sandacz
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - S Sarkar
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
| | - I A Savin
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - G Sbrizzai
- Department of Physics, University of Trieste, 34127 Trieste, Italy
- Trieste Section of INFN, 34127 Trieste, Italy
| | - H Schmieden
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
| | - A Selyunin
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - L Sinha
- Matrivani Institute of Experimental Research & Education, Calcutta-700 030, India
| | - M Slunecka
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - J Smolik
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - A Srnka
- Institute of Scientific Instruments of the CAS, 61264 Brno, Czech Republic
| | - D Steffen
- CERN, 1211 Geneva 23, Switzerland
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | | | - O Subrt
- CERN, 1211 Geneva 23, Switzerland
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - M Sulc
- Technical University in Liberec, 46117 Liberec, Czech Republic
| | - H Suzuki
- Yamagata University, Yamagata 992-8510, Japan
| | - P Sznajder
- National Centre for Nuclear Research, 02-093 Warsaw, Poland
| | - S Tessaro
- Trieste Section of INFN, 34127 Trieste, Italy
| | - F Tessarotto
- CERN, 1211 Geneva 23, Switzerland
- Trieste Section of INFN, 34127 Trieste, Italy
| | - A Thiel
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - J Tomsa
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - F Tosello
- Torino Section of INFN, 10125 Torino, Italy
| | - A Townsend
- Department of Physics, University of Illinois at Urbana-Champaign, Urbana, Illinois 61801-3080, USA
| | - V Tskhay
- Lebedev Physical Institute, 119991 Moscow, Russia
| | - S Uhl
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | | | - A Vauth
- Physikalisches Institut, Universität Bonn, 53115 Bonn, Germany
- CERN, 1211 Geneva 23, Switzerland
| | - B M Veit
- CERN, 1211 Geneva 23, Switzerland
- Institut für Kernphysik, Universität Mainz, 55099 Mainz, Germany
| | - J Veloso
- Department of Physics, University of Aveiro, I3N, 3810-193 Aveiro, Portugal
| | - B Ventura
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - A Vidon
- IRFU, CEA, Université Paris-Saclay, 91191 Gif-sur-Yvette, France
| | - M Virius
- Czech Technical University in Prague, 16636 Prague, Czech Republic
| | - M Wagner
- Helmholtz-Institut für Strahlen- und Kernphysik, Universität Bonn, 53115 Bonn, Germany
| | - S Wallner
- Physik Department, Technische Universität München, 85748 Garching, Germany
| | - K Zaremba
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
| | - P Zavada
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - M Zavertyaev
- Lebedev Physical Institute, 119991 Moscow, Russia
| | - M Zemko
- CERN, 1211 Geneva 23, Switzerland
- Faculty of Mathematics and Physics, Charles University, 18000 Prague, Czech Republic
| | - E Zemlyanichkina
- Joint Institute for Nuclear Research, 141980 Dubna, Moscow region, Russia
| | - Y Zhao
- Trieste Section of INFN, 34127 Trieste, Italy
| | - M Ziembicki
- Institute of Radioelectronics, Warsaw University of Technology, 00-665 Warsaw, Poland
| |
Collapse
|
13
|
Cecoro G, Paoletta M, Annunziata M, Laino L, Nastri L, Gimigliano F, Liguori S, Toro G, Moretti A, Guida L, Iolascon G. The role of bone anabolic drugs in the management of periodontitis: a scoping review. Eur Cell Mater 2021; 41:316-331. [PMID: 33733451 DOI: 10.22203/ecm.v041a20] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 02/05/2023] Open
Abstract
The aim of this scoping review was to summarise current knowledge about the effects of bone anabolic drugs on periodontitis, in order to identify new therapeutic strategies for preventing disease progression and reducing tooth loss. A technical expert panel (TEP) was established of 11 medical specialists, including periodontists and bone specialists that followed the PRISMA-ScR model to perform the scoping review and considered for eligibility both pre-clinical and clinical studies published in the English language up to September 2020. 716 items were initially found. After duplicate removal and screening of articles for eligibility criteria, 25 articles published between 2001 and 2019 were selected. Only studies concerning teriparatide, strontium ranelate, sclerostin antibodies and DKK1 antibodies met the eligibility criteria. In particular, only for teriparatide were there both clinical studies and experimental studies available, while for other bone anabolic drugs only animal studies were found. Available evidence about the use of bone anabolic drugs in periodontology demonstrates beneficial effects of these agents on biological pathways and histological parameters involved in periodontal tissue regeneration that suggest relevant clinical implications for the management of periodontitis.
Collapse
Affiliation(s)
| | | | | | | | | | | | | | | | - A Moretti
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", 80138 Naples,
| | | | | |
Collapse
|
14
|
Barbagallo F, Margani G, Marino EM, Moretti A, Tardo C. IMPACT OF RETROFIT OF RC FRAMES BY CLT PANELS AND FRICTION DAMPERS. Proceedings of the 8th International Conference on Computational Methods in Structural Dynamics and Earthquake Engineering (COMPDYN 2015) 2021. [DOI: 10.7712/120121.8636.18851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 09/02/2023]
|
15
|
Masiello M, Somma S, Haidukowski M, Logrieco AF, Moretti A. Genetic polymorphisms associated to SDHI fungicides resistance in selected Aspergillus flavus strains and relation with aflatoxin production. Int J Food Microbiol 2020; 334:108799. [PMID: 32799117 DOI: 10.1016/j.ijfoodmicro.2020.108799] [Citation(s) in RCA: 9] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/01/2020] [Revised: 07/17/2020] [Accepted: 07/24/2020] [Indexed: 12/18/2022]
Abstract
Aspergillus flavus is a common and ubiquitous fungal species able to colonize several agricultural commodities, in both pre- and post-harvest conditions. This species represents a very harmful plant pathogen for its ability to synthesize aflatoxin B1, responsible for human primary hepatocellular carcinoma and classified as a group I (human carcinogenic) by the International Agency for Research on Cancer. Several approaches have been proposed to control A. flavus development and related aflatoxin production in field and storage conditions. The Succinate Dehydrogenase Inhibitor (SDHI) fungicide boscalid has been shown to control A. flavus growth and aflatoxin contamination both in vitro and in field experiments. However, this compound is classified as medium-high risk fungicide for triggering fungal resistance and, indeed, resistant strains can occur on crops treated with boscalid. In this paper, we selected laboratory A. flavus strains resistant to boscalid grown on agar medium containing 50 mg/L of boscalid. In order to investigate the molecular mechanism responsible for the resistant phenotype, specific primer pairs were designed to amplify the whole SdhB, SdhC and SdhD genes. By amino acid sequence analysis, two point mutations, Tyrosine replacing Histidine at codon 249 of SdhB (H249Y) and Arginine replacing Glycine at codon 91 of SdhC (G91R), were identified. The effect of SDHI boscalid and isopyrazam on mycelial growth and conidial germination was evaluated. Both resistant genotypes showed high resistance (MIC and EC50 > 1000 mg/L) to boscalid. A positive cross-resistance was found between boscalid and isopyrazam. Specific sub-lethal doses of both fungicides (0.5 mg/L of boscalid and 0.01 mg/L of isopyrazam) interfered with the mechanisms associated to pigmentation of colonies. In particular, fungal colonies appeared depigmented lacking the typical A. flavus green colour shown on un-amended fungicide medium. A strict correlation between lack of pigmentation and increasing aflatoxin production was also observed.
Collapse
Affiliation(s)
- M Masiello
- Institute of Sciences of Food Production, Research National Council (ISPA-CNR), Via Amendola 122/O, 70126 Bari, Italy.
| | - S Somma
- Institute of Sciences of Food Production, Research National Council (ISPA-CNR), Via Amendola 122/O, 70126 Bari, Italy.
| | - M Haidukowski
- Institute of Sciences of Food Production, Research National Council (ISPA-CNR), Via Amendola 122/O, 70126 Bari, Italy.
| | - A F Logrieco
- Institute of Sciences of Food Production, Research National Council (ISPA-CNR), Via Amendola 122/O, 70126 Bari, Italy.
| | - A Moretti
- Institute of Sciences of Food Production, Research National Council (ISPA-CNR), Via Amendola 122/O, 70126 Bari, Italy.
| |
Collapse
|
16
|
Cagini C, Mariniello M, Messina M, Muzi A, Balducci C, Moretti A, Levorato L, Mencacci A. The role of ozonized oil and a combination of tobramycin/dexamethasone eye drops in the treatment of viral conjunctivitis: a randomized clinical trial. Int Ophthalmol 2020; 40:3209-3215. [PMID: 32696102 PMCID: PMC7669761 DOI: 10.1007/s10792-020-01503-4] [Citation(s) in RCA: 8] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/17/2020] [Accepted: 06/30/2020] [Indexed: 02/07/2023]
Abstract
Purpose To determine whether topical tobramycin 0.3%/dexamethasone 0.1% plus ozonized oil eye drops reduces clinical signs and infectious viral titers of presumed viral conjunctivitis more than tobramycin/dexamethasone eye drops alone. Methods Prospective, single-blind, randomized, parallel-groups trial. Eighty patients with a clinical diagnosis of presumed viral conjunctivitis were randomizedly divided into two treatment groups: a study group and a control group, 40 for each group. Patients in the study group received topical tobramycin 0.3%/dexamethasone 0.1% eye drops, plus ozonized oil eye drops, both four times daily; patients in the control group received only topical tobramycin 0.3%/dexamethasone eye drops four times daily. The treatment was for seven days in both groups. Swabs were taken from the conjunctival fornix for adenovirus PCR analysis on the day of recruitment and at seven days follow-up. Clinical signs were also recorded on the day of recruitment and at follow-up examination: the main outcomes were conjunctival injection and conjunctival chemosis, graded on a 4-point clinical scale, presence or absence of superficial punctate keratitis and subepithelial corneal infiltrates. Results No statistically significant difference was reached in adenoviral infection negativization between the two groups, although the study group showed a higher number of PCR negative results at seven days follow-up. PCR real time detected adenoviral infection in 17 of 24 patients on the day of recruitment and it was positive in 4 patients on the seventh day (viral positivity reduction of 76%). In the control group PCR was positive for adenovirus in 18 of 24 patients on the day of recruitment and in 7 patients at seven days follow-up (reduction of 61%). There was statistically significant difference on conjunctival clinical signs between the study and control groups. Significant difference was also found on superficial punctate keratitis resolution between the study and the control group. In the former superficial punctate keratitis was detected in 14 eyes on the first day and in 5 eyes after seven days while in the latter superficial punctate keratitis was found in 124 eyes on the first day and in 6 eyes on the seventh day. No difference was found in subepithelial corneal infiltrates appearance between the two groups. Conclusions The use of ozonized-oil containing eye drops in combination with topical tobramycin 0.3%/dexamethasone 0.1% eye drops four times daily seems to reduce the signs of conjunctivitis, and the duration of viral infection, although it does not affect the subepithelial corneal infiltrates appearance.
Collapse
Affiliation(s)
- C Cagini
- Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy.
| | - M Mariniello
- Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy
| | - M Messina
- Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy
| | - A Muzi
- Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy
| | - C Balducci
- Division of Ophthalmology, Department of Surgical and Biomedical Sciences, University of Perugia, Ospedale S. Maria della Misericordia, S. Andrea Delle Fratte, 06156, Perugia, Italy
| | - A Moretti
- Microbiology Unit, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy
| | - L Levorato
- Microbiology Unit, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy
| | - A Mencacci
- Microbiology Unit, Department of Medicine, University of Perugia, Ospedale S. Maria della Misericordia, Perugia, Italy
| |
Collapse
|
17
|
Cipolletta E, DI Matteo A, Brunori G, Moretti A, Grassi W, Filippucci E. THU0407 THE VALUE OF SONOGRAPHY IN THE INTERCRITICAL PHASE OF GOUT. Ann Rheum Dis 2020. [DOI: 10.1136/annrheumdis-2020-eular.1339] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/03/2022]
Abstract
Background:Disease remission is the goal of therapy for many chronic rheumatic diseases. In 2016, provisional gout remission criteria were proposed (1). To the best of our knowledge, no studies have compared ultrasound (US) findings in gouty patients with and without remission.Objectives:To determine the prevalence of US pathologic findings in patients with gout fulfilling and not fulfilling the provisional remission criteria and to investigate the value of the US findings as predictors of a gouty flare within 6 months.Methods:Patients with a diagnosis of gout according to the 2015 classification criteria (2) were recruited in this prospective, monocentric study. The following clinical information was recorded at baseline and after 6 months: number of gouty flares in the preceding 6 months, number of subcutaneous tophi, current serum urate level, and patient reported outcomes (pain visual analogue scale and patient global assessment visual analogue scale). Bilateral US assessment of the following anatomical areas was performed (3): elbow, wrist, II metacarpophalangeal joint, knee, ankle and I metatarsophalangeal joint. US evidence of tophi, aggregates, double contour sign and synovitis were recorded according to the correspondent OMERACT definitions.Results:Forty-nine patients with gout were consecutively enrolled. The remission criteria were satisfied in 9 (18.4%) patients. Monosodium urate (MSU) deposits and findings of synovitis were observed by US less frequently in patients in remission (55.6% and 22.2%), compared with those not fulfilling the criteria (100.0% and 72.5%) (p values<0.01). The US MSU total score was 1.0; 0.0–2.0 (median and inter-quartile range) for patients in remission, compared with 6.0; 5.0–7.0 for those not fulfilling the criteria (p<0.01). US synovitis total score was significantly correlated with patient global assessment (R=0.55, p<0.01), patient pain (R=0.51, p<0.01) and number of gouty attacks in the previous 6 months (R=0.36, p=0.03), whereas MSU total score was associated with the number of gouty attacks in the previous 6 months (R=0.49, p<0.01), the number of subcutaneous tophi (R=0.45, p<0.01), patient pain (R=0.41, p=0.01), patient global assessment (R=0.41, p<0.01). At logistic regression analysis, the presence of subcutaneous tophi (OR=2.8, p=0.02), CRP level (OR=6.5, p=0.04) and US synovitis score (OR=2.0, p=0.04) and were predictors of subsequent development of gouty flare within 6 months.Conclusion:This study provides new insights into the inter-critical phase of gout, highlighting the clinical relevance of US synovitis as a predictor of subsequent development of gouty flare and joint pain. Despite MSU deposits are still detectable in patients satisfying the 2016 provisional remission criteria for gout, the remission is associated with less US detected MSU deposits.References:[1]de Lautour H, et al. Development of preliminary Remission Criteria for Gout Using Delphi and 1000Minds Consensus Exercises. Arthritis Care Res 2016[2]Neogi T, et al. 2015 Gout classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 2015[3]Naredo E, et al. Ultrasound-detected musculoskeletal urate crystal deposition: which joints and what findings should be assessed for diagnosing gout? Ann Rheum Dis 2014Disclosure of Interests: :Edoardo Cipolletta: None declared, Andrea Di Matteo Grant/research support from: the publication was conducted while Dr. Di Matteo was an ARTICULUM fellow, Giada Brunori: None declared, Antonella Moretti: None declared, Walter Grassi Speakers bureau: Prof. Grassi reports personal fees from AbbVie, personal fees from Celgene, personal fees from Grünenthal, personal fees from Pfizer, personal fees from Union Chimique Belge Pharma, outside the submitted work., Emilio Filippucci Speakers bureau: Dr. Filippucci reports personal fees from AbbVie, personal fees from Bristol-Myers Squibb, personal fees from Celgene, personal fees from Roche, personal fees from Union Chimique Belge Pharma, personal fees from Pfizer, outside the submitted work.
Collapse
|
18
|
Moretti A, Fonteyne L, Giesert F, Hoppmann P, Meier AB, Bozoglu T, Baehr A, Schneider CM, Sinnecker D, Klett K, Fröhlich T, Rahman FA, Haufe T, Sun S, Jurisch V, Kessler B, Hinkel R, Dirschinger R, Martens E, Jilek C, Graf A, Krebs S, Santamaria G, Kurome M, Zakhartchenko V, Campbell B, Voelse K, Wolf A, Ziegler T, Reichert S, Lee S, Flenkenthaler F, Dorn T, Jeremias I, Blum H, Dendorfer A, Schnieke A, Krause S, Walter MC, Klymiuk N, Laugwitz KL, Wolf E, Wurst W, Kupatt C. Somatic gene editing ameliorates skeletal and cardiac muscle failure in pig and human models of Duchenne muscular dystrophy. Nat Med 2020; 26:207-214. [PMID: 31988462 PMCID: PMC7212064 DOI: 10.1038/s41591-019-0738-2] [Citation(s) in RCA: 140] [Impact Index Per Article: 35.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/07/2019] [Accepted: 12/11/2019] [Indexed: 11/09/2022]
Abstract
Frameshift mutations in the DMD gene, encoding dystrophin, cause Duchenne muscular dystrophy (DMD), leading to terminal muscle and heart failure in patients. Somatic gene editing by sequence-specific nucleases offers new options for restoring the DMD reading frame, resulting in expression of a shortened but largely functional dystrophin protein. Here, we validated this approach in a pig model of DMD lacking exon 52 of DMD (DMDΔ52), as well as in a corresponding patient-derived induced pluripotent stem cell model. In DMDΔ52 pigs1, intramuscular injection of adeno-associated viral vectors of serotype 9 carrying an intein-split Cas9 (ref. 2) and a pair of guide RNAs targeting sequences flanking exon 51 (AAV9-Cas9-gE51) induced expression of a shortened dystrophin (DMDΔ51-52) and improved skeletal muscle function. Moreover, systemic application of AAV9-Cas9-gE51 led to widespread dystrophin expression in muscle, including diaphragm and heart, prolonging survival and reducing arrhythmogenic vulnerability. Similarly, in induced pluripotent stem cell-derived myoblasts and cardiomyocytes of a patient lacking DMDΔ52, AAV6-Cas9-g51-mediated excision of exon 51 restored dystrophin expression and amelioreate skeletal myotube formation as well as abnormal cardiomyocyte Ca2+ handling and arrhythmogenic susceptibility. The ability of Cas9-mediated exon excision to improve DMD pathology in these translational models paves the way for new treatment approaches in patients with this devastating disease.
Collapse
Affiliation(s)
- A Moretti
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany.
| | - L Fonteyne
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
| | - F Giesert
- Institute of Developmental Genetics, Helmholtz Centre and Munich School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany
| | - P Hoppmann
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - A B Meier
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - T Bozoglu
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - A Baehr
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - C M Schneider
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - D Sinnecker
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - K Klett
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - T Fröhlich
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - F Abdel Rahman
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - T Haufe
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - S Sun
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - V Jurisch
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - B Kessler
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - R Hinkel
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - R Dirschinger
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - E Martens
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - C Jilek
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - A Graf
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - S Krebs
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - G Santamaria
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - M Kurome
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - V Zakhartchenko
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - B Campbell
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - K Voelse
- Reseach Unit Apoptosis in Hemopoietic Stem Cells, Helmholtz Zentrum München, German Center for Environmental Health (HMGU), Munich, Germany
| | - A Wolf
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - T Ziegler
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - S Reichert
- Department of Neurology, Friedrich Baur Institute, LMU Munich, Munich, Germany
| | - S Lee
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - F Flenkenthaler
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - T Dorn
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - I Jeremias
- Reseach Unit Apoptosis in Hemopoietic Stem Cells, Helmholtz Zentrum München, German Center for Environmental Health (HMGU), Munich, Germany
| | - H Blum
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - A Dendorfer
- Walter Brendel Centre of Experimental Medicine, University Hospital, LMU Munich, Munich, Germany
| | - A Schnieke
- Chair of Livestock Biotechnology, School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany
| | - S Krause
- Department of Neurology, Friedrich Baur Institute, LMU Munich, Munich, Germany
| | - M C Walter
- Department of Neurology, Friedrich Baur Institute, LMU Munich, Munich, Germany
| | - N Klymiuk
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - K L Laugwitz
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany
| | - E Wolf
- Chair for Molecular Animal Breeding and Biotechnology, Gene Center and Department of Veterinary Sciences, LMU Munich, Munich, Germany
- Laboratory for Functional Genome Analysis (LAFUGA), Gene Center, LMU Munich, Munich, Germany
| | - W Wurst
- Institute of Developmental Genetics, Helmholtz Centre and Munich School of Life Sciences Weihenstephan, Technical University of Munich, Munich, Germany
- German Center for Neurodegenerative Diseases, Munich Cluster for Systems Neurology (SyNergy), Munich, Germany
| | - C Kupatt
- Klinik und Poliklinik für Innere Medizin I, Klinikum rechts der Isar, Technical University Munich and German Center for Cardiovascular Research (DZHK), Munich Heart Alliance, Munich, Germany.
| |
Collapse
|
19
|
My I, Laue S, Dressen M, Schmidt F, Brade T, Dorn T, Goedel A, Lahm H, Lickert H, Krane M, Moretti A, Laugwitz KL. P1848Primary cilium-autophagy-cell cycle axis defects impair cardiac progenitor specification in hypoplastic left heart syndrome. Eur Heart J 2018. [DOI: 10.1093/eurheartj/ehy565.p1848] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Affiliation(s)
- I My
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - S Laue
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - M Dressen
- Deutsches Herzzentrum Technische Universitat, Department of cardiovascular surgery, division of experimental surgery, Munich, Germany
| | - F Schmidt
- Helmholtz Center Munich - German Research Center for Environment and Health, Institute of diabetes and regeneration research, Munich, Germany
| | - T Brade
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - T Dorn
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - A Goedel
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - H Lahm
- Deutsches Herzzentrum Technische Universitat, Department of cardiovascular surgery, division of experimental surgery, Munich, Germany
| | - H Lickert
- Helmholtz Center Munich - German Research Center for Environment and Health, Institute of diabetes and regeneration research, Munich, Germany
| | - M Krane
- Deutsches Herzzentrum Technische Universitat, Department of cardiovascular surgery, division of experimental surgery, Munich, Germany
| | - A Moretti
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| | - K.-L Laugwitz
- Hospital Rechts der Isar, Molecular Cardiology, first department of medicine, TU, Munich, Germany
| |
Collapse
|
20
|
Moretti A, Bianchi F, Abbate IV, Gherardi G, Bonavita M, Passoni E, Nazzaro G, Bramati A, Dazzani MC, Piva S, Paternò E, Frungillo N, Farina G, La Verde N. Localized morphea after breast implant for breast cancer: A case report. Tumori 2018; 104:NP25-NP28. [PMID: 29714655 DOI: 10.1177/0300891618763209] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
PURPOSE Early breast cancer follow-up guidelines for patients who underwent surgery suggest a regular and accurate clinical examination of the breast area, for an early identification of cutaneous or subcutaneous breast cancer relapse. Nonetheless, breast skin lesions arising in patients treated with mastectomy for breast cancer can be caused by several diseases. A series of diagnostic hypotheses should be considered, not only focusing on cutaneous metastasis, but also on dermatologic and systemic diseases. CASE REPORT In February 2015, a 37-year-old patient underwent a right subcutaneous mastectomy for stage IIA breast cancer. Five months after beginning adjuvant chemotherapy, she noted hyperpigmentation and thickening of the skin on the right breast. Differential diagnosis included local relapse, skin infection, lymphoma, or primary cutaneous disease, and a skin biopsy was performed. The histopathologic specimen showed full-thickness sclerosis, with features of localized morphea. Therapy with clobetasol was prescribed, with progressive resolution of the thickness. The collaboration between many professionals in a multidisciplinary team (oncologist, dermatologist, plastic surgeon, and pathologist) was crucial to achieving the diagnosis. CONCLUSION In the literature, some articles describe correlation between connective tissue diseases and silicone breast implants, but the pathogenetic mechanisms are unknown. We report a rare case of breast morphea after positioning a silicone implant in a patient who had undergone mastectomy. This clinical report represents an interesting model of multidisciplinary management of a patient with breast cancer who developed an uncommon dermatologic disease. Further studies are needed to clarify the association between silicone implants and breast morphea.
Collapse
Affiliation(s)
- A Moretti
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - F Bianchi
- 2 Department of Pathology, ASST Fatebenefratelli & Sacco, Milan, Italy
| | - I V Abbate
- 3 Department of Dermatology, Umberto I Hospital Lugo, (Ravenna), Italy
| | - G Gherardi
- 2 Department of Pathology, ASST Fatebenefratelli & Sacco, Milan, Italy
| | - M Bonavita
- 4 Department of Plastic Surgery, Fatebenefratelli, ASST Fatebenefratelli & Sacco, Milan, Italy
| | - E Passoni
- 5 Department of Dermatology, Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico, Milan, Italy
| | - G Nazzaro
- 6 Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Italy
| | - A Bramati
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - M C Dazzani
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - S Piva
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - E Paternò
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - N Frungillo
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - G Farina
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| | - N La Verde
- 1 Department of Oncology Fatebenefratelli, ASST Fatebenefratelli Sacco, Milan, Italy
| |
Collapse
|
21
|
La Verde N, Collovà E, Blasi L, Pinotti G, Bernardo A, Bonotto M, Garrone O, Brunello A, Cavazzini MG, Bareggi C, Prochilo T, Porcu L, Moretti A, Barni S. Abstract P1-14-04: Overall survival in metastatic breast cancer patients in the third millennium: Results of an Italian study. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p1-14-04] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND - Metastatic breast cancer (MBC) is a life-threatening disease. It is important to provide data about real-life MBC patients (pts) to understand the current prognostic factors. The aim of the present observational study, named COSMO (Checking Overall Survival in a MBC Observational study) is to describe the overall survival (OS) in a large cohort of MBC pts, assessing its correlation with specific prognostic factors (demographic, clinic, pathologic and biological).
PATIENTS AND METHODS - The COSMO study is a multicenter, retrospective, cohort study, developed throughout the collaboration of 31 Italian oncological centers. Data about pts diagnosed as metastatic from 01/01/2000 to 31/12/2008, were collected. The association between molecular subtypes, metastatic sites, disease free interval (DFI) and OS were assessed. Pts were classified in three subgroups, based on the biological characteristics of their tumor: luminal, HER2-positive (regardless of hormone receptor) and triple negative (TN). Metastatic sites were categorized as visceral versus non-visceral disease, only bone and central nervous system (CNS) metastases. DFI was calculated from diagnosis to first relapse only for M0 pts.
RESULTS - Of 3931 MBC pts enrolled in the study, 3720 were evaluable, with a median age of 61 years (interquartile range, IQR, 51-71). 1804 (62,1%) pts had a luminal disease, 691 (23,8%) HER2-positive, 410 (14.1%) TN. Median DFI was 3.2 years (IQR 1.7- 6.0). Regarding metastatic sites, pts with visceral disease were 2332 (63%); 826 (22,2%) pts had bone isolated metastases; in 306 (8,3%) pts, CNS metastases were reported. With a median follow up of 9 years (IQR 5.7-11.0) and 3098 (83.3%) recorded events, we founded a median OS of 2.8 years (95%CI: 2.7-2.9) years. OS was strictly depending from molecular subtypes with a better prognosis for HER2-positive versus luminal and TN MBC pts, median OS of 3.1 (95%CI 2.8-3.4), 3.0 (95%CI: 2.9-3.1) and 1.5 (95%CI: 1.3-1.7) years respectively (p-value<0.001). 525 (14,1%) pts received trastuzumab. Metastatic sites affect prognosis, with a better OS for bone disease (3.4 years, 95%CI: 3.1-3.6) versus visceral disease (2.2 years 95%CI: 2.0- 2.3). Brain metastasis correlate with the worst prognosis: OS of 1.5 years (95% CI: 0.8 – 1.7). Even DFI shows a correlation with prognosis: pts with DFI>2 years show a median OS of 3 years (95% CI: 2.9 – 3.2), while those with DFI<2 years have a median OS of 2.4 years (95% CI: 2.3-2.6); HR was 0.69 (95%CI: 0,62-0,76) for every five years of increase in DFI (p-value<0.001).
CONCLUSIONS - Molecular subtype is crucial for prognosis: HER2-positive subtype has the best prognosis, while TN subtype has the shorter OS. Having a longer DFI from diagnosis (>2 years) correlate with a better prognosis. Our study confirm that sites of metastasis affects outcome: visceral involvement correlates with poor prognosis and, particularly, pts with brain metastasis represent the worst subgroup, while pts with solely bone disease have the best prognosis. The COSMO study provides a view on the Italian landscape of MBC between 2000 and 2008, adding new insights about pts prognosis.
Citation Format: La Verde N, Collovà E, Blasi L, Pinotti G, Bernardo A, Bonotto M, Garrone O, Brunello A, Cavazzini MG, Bareggi C, Prochilo T, Porcu L, Moretti A, Barni S, On Behalf of COSMO Study Group. Overall survival in metastatic breast cancer patients in the third millennium: Results of an Italian study [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P1-14-04.
Collapse
Affiliation(s)
- N La Verde
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - E Collovà
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - L Blasi
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - G Pinotti
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - A Bernardo
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - M Bonotto
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - O Garrone
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - A Brunello
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - MG Cavazzini
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - C Bareggi
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - T Prochilo
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - L Porcu
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - A Moretti
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | - S Barni
- ASST Fatebenefratelli Sacco PO Fatebenefratelli, Milan, MI, Italy; Fondazione IRCCS Ca' Granda Ospedale Maggiore Policlinico, Milan, MI, Italy; ASST Ovest Milanese, Legnano, MI, Italy; Istituti Clinici Scientifici Maugeri, Pavia, PV, Italy; ASST Bergamo Ovest Ospedale di Treviglio, Treviglio, BG, Italy; Fondazione Poliambulanza di Brescia, Brescia, BS, Italy; ASST-Settelaghi Varese, Varese, VA, Italy; Università degli Studi di Udine, Scuola di Specializzazione in Oncologia Medica, Udine, UD, Italy; S. Croce & Carle Teaching Hospital, Oncology, Cuneo, CN, Italy; IRCCS Istituto Oncologico Veneto, Padova, PD, Italy; ASST Mantova, AO Carlo Poma, Mantova, MN, Italy; ARNAS AO Ospedale Civico Cristina Benfratelli, Palermo, PA, Italy; IRCCS - Istituto di Ricerche Farmacologiche Mario Negri, Milan, MI, Italy
| | | |
Collapse
|
22
|
Munkvold GP, Weieneth L, Proctor RH, Busman M, Blandino M, Susca A, Logrieco A, Moretti A. Pathogenicity of Fumonisin-producing and Nonproducing Strains of Aspergillus Species in Section Nigri to Maize Ears and Seedlings. Plant Dis 2018; 102:282-291. [PMID: 30673533 DOI: 10.1094/pdis-01-17-0103-re] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/09/2023]
Abstract
Species of Aspergillus section Nigri are commonly associated with maize kernels, and some strains can produce fumonisin mycotoxins. However, there is little information about the extent to which these fungi contribute to fumonisin contamination in grain, the damage they cause to maize ears, or their effects on maize seed germination and seedling health. We compared fumonisin-producing and nonproducing strains of A. niger, A. welwitschiae, A. phoenicis, A. tubingensis, and A. carbonarius from the United States and Italy in laboratory and field studies to assess their ability to contribute to fumonisin contamination, to cause maize ear rot, and to affect seed germination and seedling growth. In laboratory experiments, some strains of each Aspergillus species reduced germination or seedling growth, but there was high variability among strains within species. There were no consistent differences between fumonisin-producing and nonproducing strains. In field studies in Iowa and Illinois, strains were variable in their ability to cause ear rot symptoms, but this was independent of the ability of the Aspergillus strains to produce fumonisins. Contamination of grain with fumonisins was not consistently increased by inoculation with Aspergillus strains compared with the control, and was much greater in F. verticillioides-inoculated treatments than in Aspergillus-inoculated treatments. However, the ratio of the FB analogs FB2 and FB1 was altered by inoculation with some Aspergillus strains, indicating that FB2 production by Aspergillus strains occurred in the field. These results demonstrate the pathogenic capabilities of strains of Aspergillus in section Nigri, but suggest that their effects on maize ears and seedlings are not related to their ability to produce fumonisins, and that fumonisin contamination of grain caused by Aspergillus spp. is not as significant as that caused by Fusarium spp.
Collapse
Affiliation(s)
- G P Munkvold
- Iowa State University, Plant Pathology and Microbiology, Ames, IA
| | - L Weieneth
- Iowa State University, Plant Pathology and Microbiology, Ames, IA
| | - R H Proctor
- USDA-ARS, National Center for Agricultural Utilization Research, Peoria, IL
| | - M Busman
- USDA-ARS, National Center for Agricultural Utilization Research, Peoria, IL
| | | | | | | | | |
Collapse
|
23
|
Merla C, Andreoli G, Garino C, Vicari N, Tosi G, Guglielminetti ML, Moretti A, Biancardi A, Arlorio M, Fabbi M. Monitoring of ochratoxin A and ochratoxin-producing fungi in traditional salami manufactured in Northern Italy. Mycotoxin Res 2018; 34:107-116. [DOI: 10.1007/s12550-017-0305-y] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/23/2017] [Revised: 11/29/2017] [Accepted: 12/25/2017] [Indexed: 10/18/2022]
|
24
|
Liguori S, de Sire A, Moretti A, Sodano L, Sampaolo S, Gimigliano F, Iolascon G. Musculoskeletal impairment and functional limitations in a patient affected by mutation in the laminin a-5 gene. Funct Neurol 2018. [PMID: 29984690 DOI: 10.11138/fneur/2018.33.2.117] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
25
|
Dreßen M, Northoff B, Laue S, Neb I, Zhang Z, Gödel A, Doppler S, Deutsch M, Lahm H, Teupser D, Moretti A, Laugwitz KL, Holdt L, Lange R, Krane M. Identification of Differentially Regulated Pathways in Cardiac Development and Cardiac Gene Expression during In Vitro Cardiac Differentiation of HLHS-derived Human Induced Pluripotent Stem Cells using Transcriptome Analysis. Thorac Cardiovasc Surg 2018. [DOI: 10.1055/s-0038-1628043] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]
Affiliation(s)
- M. Dreßen
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - B. Northoff
- Institute for Laboratory Medicine, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany
| | - S. Laue
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - I. Neb
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - Z. Zhang
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - A. Gödel
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - S. Doppler
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - M. Deutsch
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - H. Lahm
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - D. Teupser
- Institute for Laboratory Medicine, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany
| | - A. Moretti
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - K.-L. Laugwitz
- First Department of Medicine, Klinikum rechts der Isar, Technical University of Munich, Munich, Germany
| | - L. Holdt
- Institute for Laboratory Medicine, University Hospital, Ludwig-Maximilian University Munich, Munich, Germany
| | - R. Lange
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| | - M. Krane
- Department of Cardiovascular Surgery, German Heart Center Munich at the Technical University of Munich, Munich, Germany
| |
Collapse
|
26
|
Jozinovic A, Battilani P, Moretti A, Streit E, Sarkanj B, Pollak L, Zivancev D, Cacic Kenjeric D, Tisma M, Strelec I. Scientific Report of the 9th International Congress “Flour-Bread ’17”. Croat J Food Sci Technol 2017. [DOI: 10.17508/cjfst.2017.9.2.19] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
|
27
|
Migliaccio S, Francomano D, Romagnoli E, Marocco C, Fornari R, Resmini G, Buffa A, Di Pietro G, Corvaglia S, Gimigliano F, Moretti A, de Sire A, Malavolta N, Lenzi A, Greco EA, Iolascon G. Persistence with denosumab therapy in women affected by osteoporosis with fragility fractures: a multicenter observational real practice study in Italy. J Endocrinol Invest 2017; 40:1321-1326. [PMID: 28589380 DOI: 10.1007/s40618-017-0701-3] [Citation(s) in RCA: 32] [Impact Index Per Article: 4.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 01/21/2017] [Accepted: 05/26/2017] [Indexed: 02/08/2023]
Abstract
BACKGROUND Persistence is commonly considered a key factor for the successful management of osteoporosis and fragility fractures. Denosumab is the first biologic agent developed for the treatment of osteoporosis with satisfying data regarding the persistence with this therapy. AIM The purpose of this multicenter observational real practice study was to evaluate the persistence with denosumab treatment in post-menopausal women affected by osteoporosis. MATERIAL/SUBJECTS AND METHODS Women were recruited in four specialized centers for the management of osteoporosis in North, Center and South of Italy. We included women with a diagnosis of post-menopausal osteoporosis, aged >50 years, able to obtain a prescription according to the Italian reimbursement criteria in force during the study period for anti-osteoporotic pharmacological treatment. They initiated a treatment with subcutaneous denosumab (Prolia®) 60 mg/every 6 months between November 2011 and May 2016. Women who had received aromatase inhibitors were excluded. Patients were assessed at baseline and every 6 months for all treatment length. Persistence data were evaluated for a total of 36 months. RESULTS Eight hundred seventy women were enrolled; mean aged 70 years, with a mean body mass index of 24.8 ± 4.1 kg/m2. At the Dual-energy X-ray absorptiometry assessment, the mean lumbar spine T-score was -2.76 ± 1.14 standard deviations (SD) and the mean femoral neck T-score was -2.49 ± 0.80 SD. During the study, the total persistence was 91.4%. Total dropouts were 75 (8.6%), higher within the initial 6-month period of treatment. CONCLUSIONS Persistence to denosumab treatment in our observational real practice study was very high. These results suggest that factors such as frequency of visits, pharmacological schedule, and opportunity to call the doctor might play an important role in the persistence and adherence to treatment to obtain maximum therapeutic effect and avoid further fragility fractures.
Collapse
Affiliation(s)
- S Migliaccio
- Section of Health Sciences, Department of Movement, Human and Health Sciences, University "Foro Italico", Piazza Lauro de Bosis, 6, 00135, Rome, Italy.
| | - D Francomano
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - E Romagnoli
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - C Marocco
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - R Fornari
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - G Resmini
- Section of Orthopaedic and Traumatology, Center of Osteoporosis and Skeletal Metabolic Diseases, ASST-Bergamo Ovest, Treviglio-Caravaggio, Italy
| | - A Buffa
- Departmental Program: Rheumatic, Connective and Bone Metabolic Diseases Management Bologna, Department of Medical and Surgical Sciences, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - G Di Pietro
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Via de Crecchio 4, 80138, Naples, Italy
| | - S Corvaglia
- Departmental Program: Rheumatic, Connective and Bone Metabolic Diseases Management Bologna, Department of Medical and Surgical Sciences, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - F Gimigliano
- Department of Physical and Mental Health and Preventive Medicine, University of Campania "Luigi Vanvitelli", Naples, Italy
| | - A Moretti
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Via de Crecchio 4, 80138, Naples, Italy
| | - A de Sire
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Via de Crecchio 4, 80138, Naples, Italy
| | - N Malavolta
- Departmental Program: Rheumatic, Connective and Bone Metabolic Diseases Management Bologna, Department of Medical and Surgical Sciences, St Orsola-Malpighi Hospital, University of Bologna, Bologna, Italy
| | - A Lenzi
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - E A Greco
- Section of Medical Pathophysiology, Endocrinology and Nutrition, Department of Experimental Medicine, Sapienza University of Rome, Rome, Italy
| | - G Iolascon
- Department of Medical and Surgical Specialties and Dentistry, University of Campania "Luigi Vanvitelli", Via de Crecchio 4, 80138, Naples, Italy.
| |
Collapse
|
28
|
Iolascon G, Gimigliano F, Moretti A, de Sire A, Migliore A, Brandi M, Piscitelli P. Early osteoarthritis: How to define, diagnose, and manage. A systematic review. Eur Geriatr Med 2017. [DOI: 10.1016/j.eurger.2017.07.008] [Citation(s) in RCA: 35] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
|
29
|
Martella L, Daniel F, Moretti A, Toma I, Lancia F, Tiberi E, Mauro E, Schirone A, Santini A, Frassoldati A. Scalp cooling: a real opportunity to prevent alopecia in breast cancer women undergoing chemotherapy? Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
30
|
Daniel F, Bannò E, Belluomini L, Martella L, Lancia F, Toma I, Moretti A, Mentrasti G, Carandina I, Marzola M, Frassoldati A. The regorafenib issue: focus on efficacy and safety in pre-treated metastatic colorectal cancer from a real world experience. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.044] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
31
|
Belluomini L, Fiorica F, Stefanelli A, Santini A, Urbini B, Daniel F, Martella L, Toma I, Lancia F, Moretti A, Bannò E, Giorgi C, Frassoldati A. Efficacy and safety of immune checkpoint inhibitor nivolumab and radiotherapy combination in advanced NSCLC. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx426.034] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
32
|
Toma I, Lancia F, Scapoli D, Frassoldati A, Panareo S, Santi I, Cittanti C, Bartolomei M, Daniel F, Moretti A, Martella L, Belluomini L, Mentrasti G. Bone pain control in Castration resistant prostate cancer (CRPC): retrospective analysis of first patients trated with Radium 223. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx423.022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
33
|
Moretti A, Lupini L, Carandina I, Bassi C, Martella L, Lancia F, Daniel F, Belluomini L, Toma I, Bannò E, Nisi C, Da Ros L, Querzoli P, Negrini M, Frassoldati A. Estrogen receptor mutation: a new strategy to overcome endocrine resistance. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx424.026] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
34
|
Carandina I, Belluomini L, Bonetti F, Urbini B, Daniel F, Lancia F, Martella L, Toma I, Moretti A, Bannò E, Nisi C, Da Ros L, Frassoldati A. Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: a systematic review and metanalysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx422.017] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
35
|
Belluomini L, Carandina I, Bonetti F, Urbini B, Daniel F, Lancia F, Martella L, Toma I, Moretti A, Bannò E, Nisi C, Da Ros L, Frassoldati A. Efficacy of anti-EGFR antibodies combined with chemotherapy for elderly patients with RAS wild-type metastatic colorectal cancer: A systematic review and metanalysis. Ann Oncol 2017. [DOI: 10.1093/annonc/mdx393.051] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
36
|
Schick R, Mekies L, Shemer Y, Hallas T, Ben-Ari M, Gherghiceanu M, Simona Pane L, My I, Freimark D, Arad M, Moretti A, Binah O. P3496Functional abnormalities in induced pluripotent stem cell-derived cardiomyocytes generated from titin-mutated dilated cardiomyopathy patients. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx504.p3496] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
37
|
Sinnecker D, Chen Z, Goedel A, My I, Dreizehnter L, Moretti A, Laugwitz KL. P2561All-optical imaging of membrane potential and calcium signalling in patient-specific hiPSC-derived cardiomyocytes. Eur Heart J 2017. [DOI: 10.1093/eurheartj/ehx502.p2561] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
38
|
Festa V, Spila Alegiani S, Chiesara F, Moretti A, Bianchi M, Dezi A, Traversa G, Koch M. Retrospective comparison of long-term ten-day/month rifaximin or mesalazine in prevention of relapse in acute diverticulitis. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2017; 21:1397-1404. [PMID: 28387885] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 06/07/2023]
Abstract
OBJECTIVE Diverticular disease (DD) of the colon has an increasing burden on health services. The effectiveness of rifaximin for the treatment of DD, is not yet established. The aim of this study is to assess the impact of long-term treatment with rifaximin or mesalazine in a 10-day schedule for the prevention of recurrent diverticulitis. PATIENTS AND METHODS This is a retrospective study. We identified all consecutive patients with DD and previous acute diverticulitis (AD) in our outpatients' database; 124 patients, were included. The recommended therapy consisted of a ten-day/month treatment with either rifaximin (400 mg bid), or mesalazine (2.4 g/daily). Primary end point was AD recurrence. RESULTS Between 2010 and 2014, 72 patients were treated with rifaximin and 52 with mesalazine. During a median follow-up of 15 months (range 1-50), we observed 21 episodes of AD among users of either rifaximin (n=7; 0.54 per 100 person-months), or mesalazine group (n=14; 1.46 per 100 person-months). Kaplan-Meier survival estimates of recurrent AD significantly differed between rifaximin and mesalazine groups (p=0.015). The multivariate Cox regression analysis showed that AD recurrence was significantly associated with therapy (rifaximin vs. mesalazine, adjusted HR 0.27; 95% CI: 0.10 to 0.72), age and gender. CONCLUSIONS Long-term treatment with rifaximin in a 10-day schedule appears more effective than mesalazine in preventing recurrent AD.
Collapse
Affiliation(s)
- V Festa
- Gastroenterology and Liver Unit, S. Filippo Neri General Hospital, Rome, Italy.
| | | | | | | | | | | | | | | |
Collapse
|
39
|
La Verde N, Moretti A, Damia G, Paternò E, Santini D, Garrone O, Fabi A, Ciccarese M, Cretella E, Torri V, Generali D, Grasso D, Puglisi F, Collovà E, Roila F, Bertolini A, Barni S, Vici P, Luigi C, Scandurra G, Bramati A, Dazzani MC, Farina G. Abstract OT1-01-05: PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer. Cancer Res 2017. [DOI: 10.1158/1538-7445.sabcs16-ot1-01-05] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
BACKGROUND Eribulin is a synthetic analogue of halichondrin B which inhibits microtubule dynamics. It has been approved in Europe for the treatment of locally advanced or metastatic breast cancer (mBC) progressed after at least two chemotherapy regimens for advanced disease. The most common adverse events (AEs) were fatigue, neutropenia and peripheral neuropathy, which occurs with an incidence ranging from 13.9% to 35%. It was severe only in a small proportion of patients, suggesting an individual susceptibility. The neurotoxicity mechanisms associated with microtubulin interfering agents have not been fully defined. Few studies reported an association between some SNPs (Single Nucleotide Polymorphisms) and microtubulin interfering agents-induced neuropathy, mainly taxanes. As the use of Eribulin becomes more widespread, a better knowledge of its safety profile, outside of clinical trials, is warranted. Given that Eribulin toxicity can result in treatment discontinuation, the ability to anticipate which patients will experience severe toxicity could allow for either early intervention or even possibly for prophylactic therapy, or for a better selection of patients eligible for treatment.
METHODS This is a multicenter, interventional, single-arm, phase IV study. The primary objective is the evaluation of the safety and tolerability profile of Eribulin in an unselected population of patients with mBC. Secondary objectives are the description of compliance to treatment and efficacy.
ENDPOINTS
•Incidence, time of onset, severity and duration of all AEs experienced during treatment with Eribulin, especially the most common reported in previous studies but also other possible unexpected toxicities.
•Association between a set of selected SNPs and the onset of any grade peripheral neuropathy. Specifically, 15 SNPs located in genes involved in microtubule dynamics or resulted from genome wide association studies, will be analyzed.
•Evaluation of quality of life during treatment using validated questionnaires.
•Assessment of dose intensity and dose schedule maintenance.
•DOT (Duration Of Treatment) and OS (Overall Survival).
STATISTICAL METHODS Summary statistics will be used in order to describe patient characteristics. Safety endpoints will be estimated by means of absolute and relative frequencies and associated 95%CI. The relationship between baseline variables and the risk of severe toxicity, as well as the relationship between SNPs and risk of neuropathy will be described by means of contingency tables and their association with outcome will be assessed by χ2 test of Mantel-Haenzel and a logistic regression model. DOT and OS will be described using Kaplan-Meier curves. A sample size of 200 patients will also allow us to get a good fitting for statistical analysis of the relationship between primary endpoint and not more than 10 factors. Regarding the relationship between SNPs and risk of neuropathy it will be feasible to screen for association about 10-15 SNPs, with known prevalence >15%.
PRESENT ACCRUAL AND TARGET ACCRUAL 98 of 200 patients were enrolled until 18/05/2016. Target accrual is open for 200 patients.
CONTACT INFORMATION Nicla La Verde: nicla.laverde@asst-fbf-sacco.it.
Citation Format: La Verde N, Moretti A, Damia G, Paternò E, Santini D, Garrone O, Fabi A, Ciccarese M, Cretella E, Torri V, Generali D, Grasso D, Puglisi F, Collovà E, Roila F, Bertolini A, Barni S, Vici P, Luigi C, Scandurra G, Bramati A, Dazzani MC, Farina G. PAINTER: Evaluation of eribulin tolerability and correlation between a set of polymorphisms and neuropathy in patients with metastatic breast cancer [abstract]. In: Proceedings of the 2016 San Antonio Breast Cancer Symposium; 2016 Dec 6-10; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2017;77(4 Suppl):Abstract nr OT1-01-05.
Collapse
Affiliation(s)
- N La Verde
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - A Moretti
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - G Damia
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - E Paternò
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - D Santini
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - O Garrone
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - A Fabi
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - M Ciccarese
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - E Cretella
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - V Torri
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - D Generali
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - D Grasso
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - F Puglisi
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - E Collovà
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - F Roila
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - A Bertolini
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - S Barni
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - P Vici
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - C Luigi
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - G Scandurra
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - A Bramati
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - MC Dazzani
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| | - G Farina
- ASST Fatebenefratelli Sacco, PO Fatebenefratelli, Milan, Italy; Istituto di Ricerche Farmacologiche Mario Negri, Milan, Italy; Campus Bio-Medico, University of Rome, Rome, Italy; Unit of Medical Oncology, S. Croce & Carle Teaching Hospital, Cuneo, Italy; Medical Oncology A, INT Regina Elena, Rome, Italy; Vito Fazi Hospital, Lecce, Italy; Medical Oncology, Azienda Sanitaria dell'Alto Adige, Bolzano, Italy; Laboratory of Methodology for Biomedical Research, IRCCS-Mario Negri Institute for Pharmacological Research, Milan, Italy; Unit of Molecular Therapy & Pharmacogenomic, AO Azienda Istituti Ospitalieri di Cremona, Cremona, Italy; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy; University Hospital of Udine, Udine, Italy; Oncology Unit, AO Ospedale Civile di Legnano, Legnano, Italy; Medical Oncology, Santa Maria Hospital, Terni, Italy; Medical Oncology Unit, A.O. Valtellina e Valchiavenna, Sondrio, Italy; Treviglio-Caravaggio Hospital, Treviglio, Italy; "Regina Elena" National Cancer Inst
| |
Collapse
|
40
|
Marenzoni ML, Morganti G, Moretta I, Crotti S, Agnetti F, Moretti A, Pitzurra L, Casagrande Proietti P, Sechi P, Cenci-Goga B, Franciosini MP. Microbiological and parasitological survey of zoonotic agents in apparently healthy feral pigeons. Pol J Vet Sci 2017; 19:309-15. [PMID: 27487504 DOI: 10.1515/pjvs-2016-0038] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]
Abstract
Microbiological and parasitological investigation was carried out on a colony of feral pigeons, located in a green area near the main hospital of a Central Italy city. One hundred pigeons were submitted to clinical examination. Cloacal swabs, grouped in pool of 4 samples, were analyzed to detect the presence of Coxiella burnetii, Chlamydia psittaci, Chlamydophila spp. using a biomolecular procedure, while individual cloacal samples were examined for Salmonella spp., Campylobacter spp., and yeasts by means of a specific culture media. An ELISA test was used to determine the presence of Giardia spp., and Cryptosporidium spp. coproantigens. Individual serological samples were also tested with the modified agglutination test (MAT) in order to detect antibodies against Toxoplasma gondii. The pigeons did not show any clinical signs. The cloacal pools proved to be negative for C. burnetii DNA while three pools were positive for C. psittaci or Chlamydophila spp. DNAs. Salmonella spp. was not detected. C. jejuni and C. coli were found in 13% and 4% of the samples, respectively. No Giardia spp. and Cryptosporidium spp. were detected. Thirty-three out of 100 samples (33%) were positive for yeast colonies. The seroprevalence for T. gondii was 8%. Although with moderate incidence, potentially zoonotic agents were present thus highlighting the need for sanitary surveillance on feral pigeon colonies.
Collapse
|
41
|
Iolascon G, Gimigliano R, Bianco M, De Sire A, Moretti A, Giusti A, Malavolta N, Migliaccio S, Migliore A, Napoli N, Piscitelli P, Resmini G, Tarantino U, Gimigliano F. Are Dietary Supplements and Nutraceuticals Effective for Musculoskeletal Health and Cognitive Function? A Scoping Review. J Nutr Health Aging 2017; 21:527-538. [PMID: 28448083 DOI: 10.1007/s12603-016-0823-x] [Citation(s) in RCA: 51] [Impact Index Per Article: 7.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/05/2023]
Abstract
OBJECTIVE The aim of our scoping review was to summarize the state of the art regarding micronutrients in order to identify which of them might effectively improve health status in the areas typically impaired in older people: bone, skeletal muscle, and cognitive function. DESIGN Scoping review. METHODS The Italian Study Group on Healthy Aging by Nutraceuticals and Dietary Supplements (HANDS) performed this scoping review, based on the following steps: doing a list of micronutrients related with musculoskeletal or cognitive functions, included in dietary supplements and nutraceuticals commercialized in Italy; planning a research on PubMed, according to an evidence-based approach, in order to the most relevant positive study for each micronutrient into each of the three areas involved (bone, skeletal muscle and cognitive function); identifying the micronutrients effective in maintaining or achieving an adequate health status in older people, specifying the effective and safe daily doses, according to the selected studies. RESULTS In literature we found 12 relevant positive studies (1 international society guidelines/recommendations, 1 systematic review, 7 randomized controlled trials, and 3 prospective cohort studies). We showed that only 16 micronutrients resulted to have appropriate scientific evidences in terms of improving musculoskeletal health and/or cognitive function in older people: beta-alanine, calcium, creatine, fluorides, leucine, magnesium, omega-3 fatty acids, potassium, vitamin B6, vitamin B9, vitamin B12, vitamin C, vitamin D, vitamin E, vitamin K2, and zinc. CONCLUSION This scoping review showed that selected micronutrients in adequate doses might have an ancillary role in musculoskeletal health and cognitive functions in older people.
Collapse
Affiliation(s)
- G Iolascon
- G. Iolascon, Department of Medical and Surgical Specialties and Dentistry, Second University of Naples, Naples, Italy,
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
42
|
Daniel F, Belluomini L, Lancia F, Martella L, Toma I, Moretti A, Bannò E, Carandina I, Marzola M, Fabbri M, Frassoldati A. Can irinotecan dose reduction according to ugt1a1 genotype avoid severe toxicities? Ann Oncol 2016. [DOI: 10.1093/annonc/mdw345.30] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
43
|
Lancia F, Marzola M, Martinello R, Borghi C, Bernardi G, Toma I, Martella L, Belluomini L, Daniel F, Moretti A, Da Ros L, Bannò E, Nisi C, Frassoldati A. Multidisciplinary management in ovarian cancer. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw338.09] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
44
|
Moretti A, Bannò E, Nisi C, Priante G, Carandina I, Rinaldi R, Frassoldati A. TILs evaluation in early stages of NSCLC. Ann Oncol 2016. [DOI: 10.1093/annonc/mdw332.28] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
45
|
Battilani P, Toscano P, Van der Fels-Klerx HJ, Moretti A, Camardo Leggieri M, Brera C, Rortais A, Goumperis T, Robinson T. Aflatoxin B1 contamination in maize in Europe increases due to climate change. Sci Rep 2016; 6:24328. [PMID: 27066906 PMCID: PMC4828719 DOI: 10.1038/srep24328] [Citation(s) in RCA: 316] [Impact Index Per Article: 39.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/09/2015] [Accepted: 03/24/2016] [Indexed: 11/28/2022] Open
Abstract
Climate change has been reported as a driver for emerging food and feed safety issues worldwide and its expected impact on the presence of mycotoxins in food and feed is of great concern. Aflatoxins have the highest acute and chronic toxicity of all mycotoxins; hence, the maximal concentration in agricultural food and feed products and their commodities is regulated worldwide. The possible change in patterns of aflatoxin occurrence in crops due to climate change is a matter of concern that may require anticipatory actions. The aim of this study was to predict aflatoxin contamination in maize and wheat crops, within the next 100 years, under a +2 °C and +5 °C climate change scenario, applying a modelling approach. Europe was virtually covered by a net, 50 × 50 km grids, identifying 2254 meshes with a central point each. Climate data were generated for each point, linked to predictive models and predictions were run consequently. Aflatoxin B1 is predicted to become a food safety issue in maize in Europe, especially in the +2 °C scenario, the most probable scenario of climate change expected for the next years. These results represent a supporting tool to reinforce aflatoxin management and to prevent human and animal exposure.
Collapse
Affiliation(s)
- P Battilani
- Università Cattolica del S. Cuore di Piacenza Faculty of Agricultural, Food and Environmental Sciences, Department of Sustainable Crop Production, via Emilia Parmense 84, 29100 Piacenza, Italy
| | - P Toscano
- National Research Council - Institute of Biometeorology (CNR-IBIMET), Via Caproni 8, 50145 Florence, Italy
| | - H J Van der Fels-Klerx
- RIKILT Wageningen UR, Department of Toxicology, Bio-assays &Novel Foods, Akkermaalsbos 2, NL-6708 WB, Wageningen, The Netherlands
| | - A Moretti
- Institute of Sciences of Food Productions, CNR, Via Amendola 122/O, 70126, Bari, Italy
| | - M Camardo Leggieri
- Università Cattolica del S. Cuore di Piacenza Faculty of Agricultural, Food and Environmental Sciences, Department of Sustainable Crop Production, via Emilia Parmense 84, 29100 Piacenza, Italy
| | - C Brera
- Istituto Superiore di Sanità, Veterinary Public Health and Food Safety Department, Viale Regina Elena 299, 00161 Rome, Italy
| | - A Rortais
- European Food Safety Authority, Scientific Committee and Emerging Risks Unit, Via Carlo Magno 1A, 43126 Parma, Italy
| | - T Goumperis
- European Food Safety Authority, Scientific Committee and Emerging Risks Unit, Via Carlo Magno 1A, 43126 Parma, Italy
| | - T Robinson
- European Food Safety Authority, Scientific Committee and Emerging Risks Unit, Via Carlo Magno 1A, 43126 Parma, Italy
| |
Collapse
|
46
|
Indelli M, Da Ros L, Urbini B, Ravaioli N, Nisi C, Moretti A, Negrini M, Frassoldati A. Next Generation Sequencing mutational analysis in “Triple Positive” breast cancer. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv336.60] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/13/2022] Open
|
47
|
Nisi C, Moretti A, Donati D, Carandina I, Da Ros L, Bannò E, Frassoldati A. A post-reaction regimen for CRC patients manifesting hypersensitivity to oxaliplatin : an effective alternative not to rule out an important option of treatment. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv340.18] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
|
48
|
Gimigliano F, Moretti A, Riccio I, Letizia Mauro G, Gimigliano R, Iolascon G. Classification of functioning and assessment of fracture risk of a large Italian osteoporotic population. The Physiatric Approach To Osteoporosis project. Eur J Phys Rehabil Med 2015; 51:529-38. [PMID: 25994371 DOI: pmid/25994371] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 02/08/2023]
Abstract
BACKGROUND Osteoporosis is a skeletal disorder characterized by compromised bone strength predisposing to an increased risk of fracture. Osteoporotic fractures cause significant morbidity, disability, and decrease in quality of life. AIM The aims of the Physiatric Approach To Osteoporosis (PATO) project were to classify osteoporotic patients with or without fragility fractures, using the Brief ICF (International Classification of Functioning, Disability and Health) Core Set for Osteoporosis and to calculate the fracture risk with the WHO FRAX® (World Health Organization Fracture Risk Assessment Tool) algorithm. DESIGN Cross-sectional survey. SETTING Seventy-nine Italian Rehabilitation Services distributed throughout Italy. POPULATION Osteoporotic patients. METHODS Each physiatrist involved in the survey was asked systematically to record demographic data, presence of fragility fractures, anamnestic risk factors included in the FRAX® Assessment Tool, ICF categories as they are listed in the Brief ICF Core Set for Osteoporosis, and treatment data of 100 osteoporotic patients (50 with at least a clinical fragility fracture and 50 without). RESULTS In accordance with the FRAX® algorithm, the 35.22% of the interviewed osteoporotic patients had a FRAX® MAJ≥20.00 and the 70.32% had a FRAX® HIP≥3.00. The most commonly impaired ICF categories were the sensation of pain for the body functions, the structure of the trunk for body structures, lifting and carrying objects for the domain of activities and participation, and products or substances for personal consumption for the environmental factors. CONCLUSION The FRAX® Assessment tool has been recognized as useful to identify people at high risk of fracture and the Brief ICF Core Set seems to be an important framework to be followed when dealing with osteoporotic patients in an outpatient setting or for clinical studies. CLINICAL REHABILITATION IMPACT Osteoporosis is well recognized as a disabling disease, posing a significant challenge for the society, therefore physiatrists should always be involved, from prevention to treatment.
Collapse
Affiliation(s)
- F Gimigliano
- Department of Physical and Mental Health and Preventive Medicine, Second University of Naples, Naples, Italy -
| | | | | | | | | | | |
Collapse
|
49
|
Moretti A, Nisi C, Carandina I, Marzola M, Bannò E, Da Ros L, Frassoldati A. Predictive value of bevacizumab –related hypertension and proteinuria in patients with mCRC in the real practice. Ann Oncol 2015. [DOI: 10.1093/annonc/mdv340.38] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
50
|
Bruno S, Bollani S, Zignego AL, Pascasio JM, Magni C, Ciancio A, Caremani M, Mangia A, Marenco S, Piovesan S, Chemello L, Babudieri S, Moretti A, Gea F, Colletta C, Perez-Alvarez R, Forns X, Larrubia JR, Arenas J, Crespo J, Calvaruso V, Ceccherini Silberstein F, Maisonneuve P, Craxì A, Calleja JL. Undetectable HCV-RNA at treatment-week 8 results in high-sustained virological response in HCV G1 treatment-experienced patients with advanced liver disease: the International Italian/Spanish Boceprevir/Peginterferon/Ribavirin Name Patients Program. J Viral Hepat 2015; 22:469-80. [PMID: 25311757 DOI: 10.1111/jvh.12342] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/16/2014] [Accepted: 09/03/2014] [Indexed: 12/11/2022]
Abstract
In many countries, first-generation protease inhibitors (PIs)/peginterferon/ribavirin (P/R) still represent the only treatment option for HCV-infected patients. Subjects with advanced disease and previous failure to P/R urgently need therapy, but they are under-represented in clinical trials. All treatment-experienced F3/4 Metavir patients who received boceprevir (BOC)+P/R in the Italian-Spanish Name Patient Program have been included in this study. Multivariate logistic regression analysis (MLR) was used to identify baseline and on-treatment predictors of SVR and adverse events (AEs). Four hundred and sixteen patients, mean age 57.7 (range 25-78 years), 70% males, 69.5% (289/416) F4, 14% (41/289) Child-Pugh class A6, 24% (70/289) with varices and 42% (173/416) prior null responders to P/R, were analysed. Overall, SVR rate (all 381 patients who received one dose of BOC) was 49%, (58% in F3, 45% in F4, 61% in relapsers, 51% in partial, 38% in null responders, and 72% in subjects with undetectable HCV-RNA at treatment-week (TW)8. Among patients with TW8 HCV-RNA ≥ 1000 IU/L, SVR was 8% (negative predictive value = 92%). Death occurred in 3 (0.8%) patients, while decompensation and infections were observed in 2.9% and 11%, respectively. At MLR, SVR predictors were TW4 HCV-RNA ≥ 1log10 -decline from baseline, undetectable TW8 HCV-RNA, prior relapse, albumin levels ≥3.5 g/dL and platelet counts ≥100 000/μL. Metavir F4, Child-Pugh A6, albumin, platelets, age and female gender were associated with serious and haematological AEs. Among treatment-experienced patients with advanced liver disease eligible for IFN-based therapy, TW8 HCV-RNA characterised the subset with either high or poor likelihood of achieving SVR. Using TW8 HCV-RNA as a futility rule, BOC/P/R appears to have a favourable benefit-risk profile.
Collapse
Affiliation(s)
- S Bruno
- AO Fatebenefratelli e Oftalmico, Milano, Italy
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|